

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use COMIRNATY safely and effectively. See full prescribing information for COMIRNATY.

**COMIRNATY® (COVID-19 Vaccine, mRNA) injectable suspension, for intramuscular use**  
**2025-2026 Formula**  
**Initial U.S. Approval: 2021**

### RECENT MAJOR CHANGES

Indications and Usage (1)	8/2025
Dosage and Administration, Preparation for Administration (2.1)	8/2025
Dosage and Administration, Administration Information (2.2)	8/2025
Dosage and Administration, Vaccination Schedule (2.3)	8/2025
Warnings and Precautions, Myocarditis and Pericarditis (5.2)	6/2025

### INDICATIONS AND USAGE

COMIRNATY is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). (1)

COMIRNATY is approved for use in individuals who are:

- 65 years of age and older, or
- 5 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. (1)

### DOSAGE AND ADMINISTRATION

**For intramuscular use. (2)**

- COMIRNATY is administered as a single 0.3 mL dose. (2.2)
- For individuals previously vaccinated with any COVID-19 vaccine, administer the dose of COMIRNATY at least 2 months after the last dose of COVID-19 vaccine. (2.3)

### DOSAGE FORMS AND STRENGTHS

COMIRNATY is an injectable suspension.

- 5 years through 11 years of age: a single dose is 0.3 mL supplied in vials with blue caps and labeled with blue borders. (3)
- 12 years of age and older: a single dose is 0.3 mL supplied in prefilled syringes labeled with gray borders. (3)

### CONTRAINDICATIONS

Known history of a severe allergic reaction (e.g., anaphylaxis) to any component of COMIRNATY. (4)

### WARNINGS AND PRECAUTIONS

- Analyses of postmarketing data from use of authorized or approved mRNA COVID-19 vaccines, including COMIRNATY, have demonstrated increased risks of myocarditis and pericarditis, with onset of symptoms typically in the first week following vaccination. The observed risk has been highest in males 12 years through 24 years of age. (5.2)
- Syncope (fainting) may occur in association with administration of injectable vaccines, including COMIRNATY. Procedures should be in place to avoid injury from fainting. (5.3)

### ADVERSE REACTIONS

- Participants 12 years of age and older: The most commonly reported adverse reactions ( $\geq 10\%$ ) after a dose of COMIRNATY were pain at the injection site (up to 90.5%), fatigue (up to 77.5%), headache (up to 75.5%), chills (up to 49.2%), muscle pain (up to 45.5%), joint pain (up to 27.5%), fever (up to 24.3%), injection site swelling (up to 11.8%), and injection site redness (up to 10.4%). (6.1)
- Participants 5 years through 11 years of age: The most commonly reported adverse reactions ( $\geq 5\%$ ) following any dose were pain at the injection site (up to 83.8%), fatigue (up to 51.9%), headache (up to 38.4%), injection site redness (up to 25.9%), injection site swelling (up to 20.0%), muscle pain (up to 18.1%), chills (up to 13.3%), fever (up to 7.8%), and joint pain (up to 7.6%). (6.1)

**To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or VAERS at 1-800-822-7967 or <http://vaers.hhs.gov>.**

**See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.**

**Revised: 2/2026**

## FULL PRESCRIBING INFORMATION: CONTENTS\*

### 1 INDICATIONS AND USAGE

### 2 DOSAGE AND ADMINISTRATION

- 2.1 Preparation for Administration
- 2.2 Administration Information
- 2.3 Vaccination Schedule

### 3 DOSAGE FORMS AND STRENGTHS

### 4 CONTRAINDICATIONS

### 5 WARNINGS AND PRECAUTIONS

- 5.1 Management of Acute Allergic Reactions
- 5.2 Myocarditis and Pericarditis
- 5.3 Syncope
- 5.4 Altered Immunocompetence
- 5.5 Limitation of Effectiveness

### 6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

### 8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Immunocompromised Individuals

### 11 DESCRIPTION

### 12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

### 13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

### 14 CLINICAL STUDIES

14.1 Adults and Adolescents 12 Years of Age and Older

14.2 Children 5 Years Through 11 Years of Age

### 15 REFERENCES

### 16 HOW SUPPLIED/STORAGE AND HANDLING

### 17 PATIENT COUNSELING INFORMATION

\* Sections or subsections omitted from the full prescribing information are not listed.

## FULL PRESCRIBING INFORMATION

### 1 INDICATIONS AND USAGE

COMIRNATY is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

COMIRNATY is approved for use in individuals who are:

- 65 years of age and older, or
- 5 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

### 2 DOSAGE AND ADMINISTRATION

**For intramuscular use.**

#### 2.1 Preparation for Administration

COMIRNATY Single-Dose Prefilled Syringes for Individuals 65 Years of Age and Older and Individuals 12 Years Through 64 Years of Age with at Least One Underlying Condition that Puts Them at High Risk for Severe Outcomes from COVID-19:

- Verify that the label on the prefilled syringe states 2025-2026 Formula.
- If prefilled syringe has been frozen, discard.
- Do not shake.
- Remove tip cap by slowly turning the cap counterclockwise while holding the Luer lock and attach a sterile needle. Use immediately. If COMIRNATY cannot be used immediately, it must be used within 4 hours.

COMIRNATY Single-Dose Vials for Individuals 5 Years Through 11 Years of Age with at Least One Underlying Condition that Puts Them at High Risk for Severe Outcomes from COVID-19:

- Verify that the label on the vial states 2025-2026 Formula.
- If vial is frozen, thaw vial in the refrigerator [2°C to 8°C (35°F to 46°F) for up to 2 hours] or at room temperature [up to 25°C (77°F) for 30 minutes] [*see How Supplied/Storage and Handling (16)*].
- Prior to use, mix by inverting vial gently 10 times. Do not shake.
- Withdraw a single 0.3 mL dose using a sterile needle and syringe.
- Discard vial and any excess volume.

#### 2.2 Administration Information

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. For the prefilled syringe, the vaccine will be a white to off-white suspension and for the vial, the vaccine will be clear to slightly opalescent suspension. Do not administer if vaccine is discolored or contains particulate matter.

Administer the 0.3 mL dose intramuscularly immediately after preparation. For the prefilled syringe, administer the entire volume to deliver a single 0.3 mL dose.

## 2.3 Vaccination Schedule

COMIRNATY is administered as a single dose for individuals 5 years of age and older.

For individuals previously vaccinated with any COVID-19 vaccine, administer the dose of COMIRNATY at least 2 months after the last dose of COVID-19 vaccine.

## 3 DOSAGE FORMS AND STRENGTHS

COMIRNATY is an injectable suspension.

- For individuals 5 years through 11 years of age: a single dose is 0.3 mL supplied in vials with blue caps and labeled with blue borders.
- For individuals 12 years of age and older: a single dose is 0.3 mL supplied in prefilled syringes labeled with gray borders.

## 4 CONTRAINDICATIONS

Do not administer COMIRNATY to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of COMIRNATY [see *Description (11)*] or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of a Pfizer-BioNTech COVID-19 vaccine.

## 5 WARNINGS AND PRECAUTIONS

### 5.1 Management of Acute Allergic Reactions

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of COMIRNATY.

### 5.2 Myocarditis and Pericarditis

Analyses of postmarketing data from use of authorized or approved mRNA COVID-19 vaccines, including COMIRNATY, have demonstrated increased risks of myocarditis and pericarditis, with onset of symptoms typically in the first week following vaccination. The observed risk has been highest in males 12 years through 24 years of age.

Based on analyses of commercial health insurance claims data from inpatient and outpatient settings, the estimated unadjusted incidence of myocarditis and/or pericarditis during the period 1 through 7 days following administration of the 2023-2024 Formula of mRNA COVID-19 vaccines was approximately 8 cases per million doses in individuals 6 months through 64 years of age and approximately 27 cases per million doses in males 12 through 24 years of age.

Although some individuals with myocarditis and/or pericarditis following administration of mRNA COVID-19 vaccines have required intensive care support, available data suggest that individuals typically have resolution of symptoms within a few days with conservative management.

Follow-up information on cardiovascular outcomes in hospitalized patients who had been diagnosed with COVID-19 vaccine-associated myocarditis is available from a longitudinal retrospective observational study. Most of these patients had received a two-dose primary series of an mRNA COVID-19 vaccine prior to their

diagnosis. In this study, at a median follow-up of approximately 5 months postvaccination, persistence of abnormal cardiac magnetic resonance imaging (CMR) findings that are a marker for myocardial injury was common. The clinical and prognostic significance of these CMR findings is not known<sup>1</sup> [see *Adverse Reactions (6.2)*].

Information is not yet available about potential long-term sequelae of myocarditis or pericarditis following administration of mRNA COVID-19 vaccines.

The Centers for Disease Control and Prevention (CDC) has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html>).

### 5.3 Syncope

Syncope (fainting) may occur in association with administration of injectable vaccines, including COMIRNATY. Procedures should be in place to avoid injury from fainting.

### 5.4 Altered Immunocompetence

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to COMIRNATY [see *Use in Specific Populations (8.6)*].

### 5.5 Limitation of Effectiveness

COMIRNATY may not protect all vaccine recipients.

## 6 ADVERSE REACTIONS

An overview of clinical studies contributing to the safety assessment of COMIRNATY is provided in Table 1 and Table 2. Participants in these clinical studies received a single dose or a 2-dose series administered 3 weeks apart (referred to as a primary series) and subsequent doses referred to as booster doses.

**Table 1: Clinical Studies – Adults and Adolescents 12 Years of Age and Older**

Study	Age Group	Vaccine Strain Composition	Dosing	Number of Participants
<b>Primary Series</b>				
Study 1 (NCT04380701)	18 through 55 years of age	Original <sup>a</sup>	Primary series	60
Study 2 (NCT04368728)	16 years of age and older	Original <sup>a</sup>	Primary series	22,026 <sup>b</sup>
	12 through 15 years of age	Original <sup>a</sup>	Primary series	1,131 <sup>b</sup>
<b>Booster Dose</b>				
Study 4 (NCT04955626)	16 years of age and older	Original <sup>a</sup>	1 <sup>st</sup> booster	5,081 <sup>b</sup>
Study 2 (NCT04368728)	18 through 55 years of age	Original <sup>a</sup>	1 <sup>st</sup> booster	306
Study 4 (NCT04955626)	12 through 17 years of age	Original <sup>a</sup>	1 <sup>st</sup> booster	65

Study	Age Group	Vaccine Strain Composition	Dosing	Number of Participants
Study 2 (NCT04368728)	12 through 15 years of age	Original <sup>a</sup>	1 <sup>st</sup> booster	825
Study 5 (NCT05472038)	12 years of age and older	Original and Omicron BA.4/BA.5 <sup>c</sup>	2 <sup>nd</sup> booster	726
<b>Concomitant Administration</b>				
Study 8 (NCT05310084)	18 through 64 years of age	Original <sup>a</sup>	2 <sup>nd</sup> booster administered alone or concomitantly with Influenza Vaccine <sup>d</sup>	1,128

Abbreviation: SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

- COMIRNATY encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain [Original, 30 mcg nucleoside-modified messenger RNA (modRNA)].
- Received COMIRNATY during placebo-control period.
- Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original) and Omicron variant lineages BA.4 and BA.5 (Omicron BA.4/BA.5), previously authorized as Pfizer-BioNTech COVID-19 Vaccine, Bivalent (30 mcg modRNA).
- Influenza Vaccine (Afluria<sup>®</sup> Quadrivalent).

**Table 2: Clinical Studies – Children 5 Years Through 11 Years of Age**

Study	Age Group	Vaccine Strain Composition	Dosing	Number of Participants
<b>Primary Series</b>				
Study 3 (NCT04816643)	5 through 11 years of age	Original <sup>a</sup>	Primary series	3,109 <sup>b</sup>
<b>Booster Dose</b>				
Study 3 (NCT04816643)	5 through 11 years of age	Original <sup>a</sup>	1 <sup>st</sup> booster	2,408
Study 6 (NCT05543616)	5 through 11 years of age	Original and Omicron BA.4/BA.5 <sup>c</sup>	2 <sup>nd</sup> booster	113
<b>Single Dose</b>				
Study 6 (NCT05543616)	5 through 11 years of age	Omicron XBB.1.5 <sup>d</sup>	Single dose	310

Abbreviation: SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

- COMIRNATY encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original, 10 mcg modRNA).
- Received COMIRNATY during placebo-control period.
- Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original) and Omicron variant lineages BA.4 and BA.5 (Omicron BA.4/BA.5), previously authorized as Pfizer-BioNTech COVID-19 Vaccine, Bivalent (10 mcg modRNA).
- COMIRNATY encoding the viral spike (S) glycoprotein of SARS-CoV-2 Omicron XBB.1.5 (10 mcg modRNA).

*Participants 12 years of age and older:* The most commonly reported adverse reactions ( $\geq 10\%$ ) after a dose of COMIRNATY were pain at the injection site (up to 90.5%), fatigue (up to 77.5%), headache (up to 75.5%), chills (up to 49.2%), muscle pain (up to 45.5%), joint pain (up to 27.5%), fever (up to 24.3%), injection site swelling (up to 11.8%), and injection site redness (up to 10.4%).

*Participants 5 years through 11 years of age:* The most commonly reported adverse reactions ( $\geq 5\%$ ) following any dose were pain at the injection site (up to 83.8%), fatigue (up to 51.9%), headache (up to 38.4%), injection

site redness (up to 25.9%), injection site swelling (up to 20.0%), muscle pain (up to 18.1%), chills (up to 13.3%), fever (up to 7.8%), and joint pain (up to 7.6%).

## **6.1 Clinical Trials Experience**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.

### Adults and Adolescents 12 Years of Age and Older

#### *Two-Dose Series (Original Monovalent) in Vaccine-Naïve Individuals 16 Years of Age and Older*

The safety of a 2-dose primary series of COMIRNATY was evaluated in participants 12 years of age and older in 2 clinical studies conducted in Germany (Study 1), United States, Argentina, Brazil, Turkey, South Africa, and Germany (Study 2). Study BNT162-01 (Study 1) was a Phase 1/2, 2-part, dose-escalation trial that enrolled 60 participants, 18 through 55 years of age and 36 participants, 56 through 85 years of age. Study 2 was a Phase 1/2/3 multicenter, randomized, saline placebo-controlled, double-blinded (Phase 2/3), dose-finding, vaccine candidate-selection and efficacy study that enrolled approximately 44,000 participants 16 years of age or older (22,026 COMIRNATY; 22,021 placebo).

Study 2 included 200 participants with confirmed stable human immunodeficiency virus (HIV) infection. Confirmed stable HIV infection was defined as documented viral load <50 copies/mL and CD4 count >200 cells/mm<sup>3</sup> within 6 months before enrollment, and on stable antiretroviral therapy for at least 6 months. HIV-positive participants are included in the safety population but are summarized separately in the safety analyses.

In Study 2, participants 16 years and older in the reactogenicity subset were monitored using an electronic diary for solicited local and systemic reactions and use of antipyretic medication after each vaccination. Participants were also monitored for unsolicited adverse events throughout the study (from Dose 1 through 1 month [all unsolicited adverse events] or through 6 months [serious adverse events] after the last vaccination). Tables 3 through 6 present the frequency and severity of solicited local and systemic reactions, respectively, within 7 days following Dose 1 or Dose 2 of COMIRNATY.

At the time of the analysis of Study 2 with a data cutoff of March 13, 2021, there were 25,651 (58.2%) participants (13,031 COMIRNATY; 12,620 placebo) 16 years of age and older followed for ≥4 months after the second dose.

Demographic characteristics in Study 2 were generally similar with regard to age, sex, race, and ethnicity among participants who received COMIRNATY and those who received placebo. Overall, among the total participants who received either COMIRNATY or placebo, 50.9% were male, 49.1% were female, 79.3% were 16 through 64 years of age, 20.7% were 65 years of age and older, 82.0% were White, 9.6% were Black or African American, 25.9% were Hispanic/Latino, 4.3% were Asian, and 1.0% were American Indian or Alaska Native.

#### Local and Systemic Solicited Adverse Reactions

In participants 16 through 55 years of age after receiving Dose 2, the mean duration of pain at the injection site was 2.5 days (range 1 to 70 days), for redness 2.2 days (range 1 to 9 days), and for swelling 2.1 days (range 1 to 8 days) for participants in the COMIRNATY group.

In participants 56 years of age and older after receiving Dose 2, the mean duration of pain at the injection site was 2.4 days (range 1 to 36 days), for redness 3.0 days (range 1 to 34 days), and for swelling 2.6 days (range 1 to 34 days) for participants in the COMIRNATY group.

**Table 3: Study 2 – Frequency and Percentages of Participants With Solicited Local Reactions, by Maximum Severity, Within 7 Days After Each Dose – Participants 16 Through 55 Years of Age – Reactogenicity Subset of the Safety Population\***

	<b>COMIRNATY<sup>†</sup> Dose 1 N<sup>a</sup>=2899 n<sup>b</sup> (%)</b>	<b>Placebo Dose 1 N<sup>a</sup>=2908 n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>†</sup> Dose 2 N<sup>a</sup>=2682 n<sup>b</sup> (%)</b>	<b>Placebo Dose 2 N<sup>a</sup>=2684 n<sup>b</sup> (%)</b>
<b>Redness<sup>c</sup></b>				
Any (>2.0 cm)	156 (5.4)	28 (1.0)	151 (5.6)	18 (0.7)
Mild	113 (3.9)	19 (0.7)	90 (3.4)	12 (0.4)
Moderate	36 (1.2)	6 (0.2)	50 (1.9)	6 (0.2)
Severe	7 (0.2)	3 (0.1)	11 (0.4)	0
<b>Swelling<sup>c</sup></b>				
Any (>2.0 cm)	184 (6.3)	16 (0.6)	183 (6.8)	5 (0.2)
Mild	124 (4.3)	6 (0.2)	110 (4.1)	3 (0.1)
Moderate	54 (1.9)	8 (0.3)	66 (2.5)	2 (0.1)
Severe	6 (0.2)	2 (0.1)	7 (0.3)	0
<b>Pain at the injection site<sup>d</sup></b>				
Any	2426 (83.7)	414 (14.2)	2101 (78.3)	312 (11.6)
Mild	1464 (50.5)	391 (13.4)	1274 (47.5)	284 (10.6)
Moderate	923 (31.8)	20 (0.7)	788 (29.4)	28 (1.0)
Severe	39 (1.3)	3 (0.1)	39 (1.5)	0

Notes: Reactions were collected in the electronic diary (e-diary) from Day 1 to Day 7 after vaccination.

No Grade 4 solicited local reactions were reported in participants 16 through 55 years of age.

\* Randomized participants in the safety analysis population who received at least 1 dose of the study intervention. Participants with chronic, stable HIV infection were excluded.

† Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose. The N for each reaction was the same, therefore, this information was included in the column header.

b. n = Number of participants with the specified reaction.

c. Mild: >2.0 to ≤5.0 cm; Moderate: >5.0 to ≤10.0 cm; Severe: >10.0 cm.

d. Mild: does not interfere with activity; Moderate: interferes with activity; Severe: prevents daily activity.

**Table 4: Study 2 – Frequency and Percentages of Participants With Solicited Systemic Reactions, by Maximum Severity, Within 7 Days After Each Dose – Participants 16 Through 55 Years of Age – Reactogenicity Subset of the Safety Population\***

	<b>COMIRNATY<sup>†</sup> Dose 1 N<sup>a</sup>=2899 n<sup>b</sup> (%)</b>	<b>Placebo Dose 1 N<sup>a</sup>=2908 n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>†</sup> Dose 2 N<sup>a</sup>=2682 n<sup>b</sup> (%)</b>	<b>Placebo Dose 2 N<sup>a</sup>=2684 n<sup>b</sup> (%)</b>
<b>Fever</b>				
≥38.0°C	119 (4.1)	25 (0.9)	440 (16.4)	11 (0.4)
≥38.0°C to 38.4°C	86 (3.0)	16 (0.6)	254 (9.5)	5 (0.2)
>38.4°C to 38.9°C	25 (0.9)	5 (0.2)	146 (5.4)	4 (0.1)
>38.9°C to 40.0°C	8 (0.3)	4 (0.1)	39 (1.5)	2 (0.1)

	<b>COMIRNATY<sup>†</sup></b> <b>Dose 1</b> <b>N<sup>a</sup>=2899</b> <b>n<sup>b</sup> (%)</b>	<b>Placebo</b> <b>Dose 1</b> <b>N<sup>a</sup>=2908</b> <b>n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>†</sup></b> <b>Dose 2</b> <b>N<sup>a</sup>=2682</b> <b>n<sup>b</sup> (%)</b>	<b>Placebo</b> <b>Dose 2</b> <b>N<sup>a</sup>=2684</b> <b>n<sup>b</sup> (%)</b>
>40.0°C	0	0	1 (0.0)	0
<b>Fatigue<sup>c</sup></b>				
Any	1431 (49.4)	960 (33.0)	1649 (61.5)	614 (22.9)
Mild	760 (26.2)	570 (19.6)	558 (20.8)	317 (11.8)
Moderate	630 (21.7)	372 (12.8)	949 (35.4)	283 (10.5)
Severe	41 (1.4)	18 (0.6)	142 (5.3)	14 (0.5)
<b>Headache<sup>c</sup></b>				
Any	1262 (43.5)	975 (33.5)	1448 (54.0)	652 (24.3)
Mild	785 (27.1)	633 (21.8)	699 (26.1)	404 (15.1)
Moderate	444 (15.3)	318 (10.9)	658 (24.5)	230 (8.6)
Severe	33 (1.1)	24 (0.8)	91 (3.4)	18 (0.7)
<b>Chills<sup>c</sup></b>				
Any	479 (16.5)	199 (6.8)	1015 (37.8)	114 (4.2)
Mild	338 (11.7)	148 (5.1)	477 (17.8)	89 (3.3)
Moderate	126 (4.3)	49 (1.7)	469 (17.5)	23 (0.9)
Severe	15 (0.5)	2 (0.1)	69 (2.6)	2 (0.1)
<b>Vomiting<sup>d</sup></b>				
Any	34 (1.2)	36 (1.2)	58 (2.2)	30 (1.1)
Mild	29 (1.0)	30 (1.0)	42 (1.6)	20 (0.7)
Moderate	5 (0.2)	5 (0.2)	12 (0.4)	10 (0.4)
Severe	0	1 (0.0)	4 (0.1)	0
<b>Diarrhea<sup>c</sup></b>				
Any	309 (10.7)	323 (11.1)	269 (10.0)	205 (7.6)
Mild	251 (8.7)	264 (9.1)	219 (8.2)	169 (6.3)
Moderate	55 (1.9)	58 (2.0)	44 (1.6)	35 (1.3)
Severe	3 (0.1)	1 (0.0)	6 (0.2)	1 (0.0)
<b>New or worsened muscle pain<sup>c</sup></b>				
Any	664 (22.9)	329 (11.3)	1055 (39.3)	237 (8.8)
Mild	353 (12.2)	231 (7.9)	441 (16.4)	150 (5.6)
Moderate	296 (10.2)	96 (3.3)	552 (20.6)	84 (3.1)
Severe	15 (0.5)	2 (0.1)	62 (2.3)	3 (0.1)
<b>New or worsened joint pain<sup>c</sup></b>				
Any	342 (11.8)	168 (5.8)	638 (23.8)	147 (5.5)
Mild	200 (6.9)	112 (3.9)	291 (10.9)	82 (3.1)
Moderate	137 (4.7)	55 (1.9)	320 (11.9)	61 (2.3)
Severe	5 (0.2)	1 (0.0)	27 (1.0)	4 (0.1)
<b>Use of antipyretic or pain medication<sup>f</sup></b>				
	805 (27.8)	398 (13.7)	1213 (45.2)	320 (11.9)

Notes: Reactions and use of antipyretic or pain medication were collected in the electronic diary (e-diary) from Day 1 to Day 7 after each dose.

No Grade 4 solicited systemic reactions were reported in participants 16 through 55 years of age.

\* Randomized participants in the safety analysis population who received at least 1 dose of the study intervention. Participants with chronic, stable HIV infection were excluded.

† Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

- a. N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose. The N for each reaction or use of antipyretic or pain medication was the same, therefore, this information was included in the column header.
- b. n = Number of participants with the specified reaction.
- c. Mild: does not interfere with activity; Moderate: some interference with activity; Severe: prevents daily activity.
- d. Mild: 1 to 2 times in 24 hours; Moderate: >2 times in 24 hours; Severe: requires intravenous hydration.
- e. Mild: 2 to 3 loose stools in 24 hours; Moderate: 4 to 5 loose stools in 24 hours; Severe: 6 or more loose stools in 24 hours.
- f. Severity was not collected for use of antipyretic or pain medication.

**Table 5: Study 2 – Frequency and Percentages of Participants With Solicited Local Reactions, by Maximum Severity, Within 7 Days After Each Dose – Participants 56 Years of Age and Older – Reactogenicity Subset of the Safety Population\***

	<b>COMIRNATY<sup>†</sup> Dose 1 N<sup>a</sup>=2008 n<sup>b</sup> (%)</b>	<b>Placebo Dose 1 N<sup>a</sup>=1989 n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>†</sup> Dose 2 N<sup>a</sup>=1860 n<sup>b</sup> (%)</b>	<b>Placebo Dose 2 N<sup>a</sup>=1833 n<sup>b</sup> (%)</b>
<b>Redness<sup>c</sup></b>				
Any (>2.0 cm)	106 (5.3)	20 (1.0)	133 (7.2)	14 (0.8)
Mild	71 (3.5)	13 (0.7)	65 (3.5)	10 (0.5)
Moderate	30 (1.5)	5 (0.3)	58 (3.1)	3 (0.2)
Severe	5 (0.2)	2 (0.1)	10 (0.5)	1 (0.1)
<b>Swelling<sup>c</sup></b>				
Any (>2.0 cm)	141 (7.0)	23 (1.2)	145 (7.8)	13 (0.7)
Mild	87 (4.3)	11 (0.6)	80 (4.3)	5 (0.3)
Moderate	52 (2.6)	12 (0.6)	61 (3.3)	7 (0.4)
Severe	2 (0.1)	0	4 (0.2)	1 (0.1)
<b>Pain at the injection site<sup>d</sup></b>				
Any (>2.0 cm)	1408 (70.1)	185 (9.3)	1230 (66.1)	143 (7.8)
Mild	1108 (55.2)	177 (8.9)	873 (46.9)	138 (7.5)
Moderate	296 (14.7)	8 (0.4)	347 (18.7)	5 (0.3)
Severe	4 (0.2)	0	10 (0.5)	0

Notes: Reactions were collected in the electronic diary (e-diary) from Day 1 to Day 7 after vaccination.

No Grade 4 solicited local reactions were reported in participants 56 years of age and older.

\* Randomized participants in the safety analysis population who received at least 1 dose of the study intervention. Participants with chronic, stable HIV infection were excluded.

† Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose. The N for each reaction was the same, therefore, the information was included in the column header.

b. n = Number of participants with the specified reaction.

c. Mild: >2.0 to ≤5.0 cm; Moderate: >5.0 to ≤10.0 cm; Severe: >10.0 cm.

d. Mild: does not interfere with activity; Moderate: interferes with activity; Severe: prevents daily activity.

**Table 6: Study 2 – Frequency and Percentages of Participants With Solicited Systemic Reactions, by Maximum Severity, Within 7 Days After Each Dose – Participants 56 Years of Age and Older – Reactogenicity Subset of the Safety Population\***

	<b>COMIRNATY<sup>†</sup> Dose 1 N<sup>a</sup>=2008 n<sup>b</sup> (%)</b>	<b>Placebo Dose 1 N<sup>a</sup>=1989 n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>†</sup> Dose 2 N<sup>a</sup>=1860 n<sup>b</sup> (%)</b>	<b>Placebo Dose 2 N<sup>a</sup>=1833 n<sup>b</sup> (%)</b>
<b>Fever</b>				
≥38.0°C	26 (1.3)	8 (0.4)	219 (11.8)	4 (0.2)
≥38.0°C to 38.4°C	23 (1.1)	3 (0.2)	158 (8.5)	2 (0.1)

	<b>COMIRNATY<sup>†</sup> Dose 1 N<sup>a</sup>=2008 n<sup>b</sup> (%)</b>	<b>Placebo Dose 1 N<sup>a</sup>=1989 n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>†</sup> Dose 2 N<sup>a</sup>=1860 n<sup>b</sup> (%)</b>	<b>Placebo Dose 2 N<sup>a</sup>=1833 n<sup>b</sup> (%)</b>
>38.4°C to 38.9°C	2 (0.1)	3 (0.2)	54 (2.9)	1 (0.1)
>38.9°C to 40.0°C	1 (0.0)	2 (0.1)	7 (0.4)	1 (0.1)
>40.0°C	0	0	0	0
<b>Fatigue<sup>c</sup></b>				
Any	677 (33.7)	447 (22.5)	949 (51.0)	306 (16.7)
Mild	415 (20.7)	281 (14.1)	391 (21.0)	183 (10.0)
Moderate	259 (12.9)	163 (8.2)	497 (26.7)	121 (6.6)
Severe	3 (0.1)	3 (0.2)	60 (3.2)	2 (0.1)
Grade 4	0	0	1 (0.1)	0
<b>Headache<sup>c</sup></b>				
Any	503 (25.0)	363 (18.3)	733 (39.4)	259 (14.1)
Mild	381 (19.0)	267 (13.4)	464 (24.9)	189 (10.3)
Moderate	120 (6.0)	93 (4.7)	256 (13.8)	65 (3.5)
Severe	2 (0.1)	3 (0.2)	13 (0.7)	5 (0.3)
<b>Chills<sup>c</sup></b>				
Any	130 (6.5)	69 (3.5)	435 (23.4)	57 (3.1)
Mild	102 (5.1)	49 (2.5)	229 (12.3)	45 (2.5)
Moderate	28 (1.4)	19 (1.0)	185 (9.9)	12 (0.7)
Severe	0	1 (0.1)	21 (1.1)	0
<b>Vomiting<sup>d</sup></b>				
Any	10 (0.5)	9 (0.5)	13 (0.7)	5 (0.3)
Mild	9 (0.4)	9 (0.5)	10 (0.5)	5 (0.3)
Moderate	1 (0.0)	0	1 (0.1)	0
Severe	0	0	2 (0.1)	0
<b>Diarrhea<sup>c</sup></b>				
Any	168 (8.4)	130 (6.5)	152 (8.2)	102 (5.6)
Mild	137 (6.8)	109 (5.5)	125 (6.7)	76 (4.1)
Moderate	27 (1.3)	20 (1.0)	25 (1.3)	22 (1.2)
Severe	4 (0.2)	1 (0.1)	2 (0.1)	4 (0.2)
<b>New or worsened muscle pain<sup>c</sup></b>				
Any	274 (13.6)	165 (8.3)	537 (28.9)	99 (5.4)
Mild	183 (9.1)	111 (5.6)	229 (12.3)	65 (3.5)
Moderate	90 (4.5)	51 (2.6)	288 (15.5)	33 (1.8)
Severe	1 (0.0)	3 (0.2)	20 (1.1)	1 (0.1)
<b>New or worsened joint pain<sup>c</sup></b>				
Any	175 (8.7)	124 (6.2)	353 (19.0)	72 (3.9)
Mild	119 (5.9)	78 (3.9)	183 (9.8)	44 (2.4)
Moderate	53 (2.6)	45 (2.3)	161 (8.7)	27 (1.5)
Severe	3 (0.1)	1 (0.1)	9 (0.5)	1 (0.1)
<b>Use of antipyretic or pain medication<sup>f</sup></b>	<b>382 (19.0)</b>	<b>224 (11.3)</b>	<b>688 (37.0)</b>	<b>170 (9.3)</b>

Notes: Reactions and use of antipyretic or pain medication were collected in the electronic diary (e-diary) from Day 1 to Day 7 after each dose.

The only Grade 4 solicited systemic reaction reported in participants 56 years of age and older was fatigue.

- \* Randomized participants in the safety analysis population who received at least 1 dose of the study intervention. Participants with chronic, stable HIV infection were excluded.
- † Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).
- a. N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose. N for each reaction or use of antipyretic or pain medication was the same, therefore was included in the column header.
- b. n = Number of participants with the specified reaction.
- c. Mild: does not interfere with activity; Moderate: some interference with activity; Severe: prevents daily activity; Grade 4 reactions were defined in the clinical study protocol as emergency room visit or hospitalization for severe fatigue, severe headache, severe chills, severe muscle pain, or severe joint pain.
- d. Mild: 1 to 2 times in 24 hours; Moderate: >2 times in 24 hours; Severe: requires intravenous hydration; Grade 4 emergency visit or hospitalization for severe vomiting.
- e. Mild: 2 to 3 loose stools in 24 hours; Moderate: 4 to 5 loose stools in 24 hours; Severe: 6 or more loose stools in 24 hours; Grade 4: emergency room or hospitalization for severe diarrhea.
- f. Severity was not collected for use of antipyretic or pain medication.

In participants with chronic, stable HIV infection the frequencies of solicited local and systemic adverse reactions were similar to or lower than those observed for all participants 16 years of age and older.

### Unsolicited Adverse Events

Overall, 11,253 (51.1%) participants 16 years of age and older in the COMIRNATY group and 11,316 (51.4%) participants in the placebo group had follow-up time between  $\geq 4$  months to <6 months after Dose 2 in the blinded placebo-controlled follow-up period with an additional 1,778 (8.1%) and 1,304 (5.9%) with  $\geq 6$  months of blinded follow-up time in the COMIRNATY and placebo groups, respectively.

A total of 12,006 (54.5%) participants originally randomized to COMIRNATY had  $\geq 6$  months total (blinded and unblinded) follow-up after Dose 2.

In an analysis of all unsolicited adverse events reported following any dose, through 1 month after Dose 2, in participants 16 years of age and older (N = 43,847; 21,926 COMIRNATY group vs. 21,921 placebo group), those assessed as adverse reactions not already captured by solicited local and systemic reactions were nausea (274 vs. 87), malaise (130 vs. 22), lymphadenopathy (83 vs. 7), asthenia (76 vs. 25), decreased appetite (39 vs. 9), hyperhidrosis (31 vs. 9), lethargy (25 vs. 6), and night sweats (17 vs. 3).

In analyses of all unsolicited adverse events in Study 2 from Dose 1 up to the participant unblinding date, 58.2% of study participants had at least 4 months of follow-up after Dose 2. Among participants 16 through 55 years of age who received at least 1 dose of study vaccine, 12,995 of whom received COMIRNATY and 13,026 of whom received placebo, unsolicited adverse events were reported by 4,396 (33.8%) participants in the COMIRNATY group and 2,136 (16.4%) participants in the placebo group. In a similar analysis in participants 56 years of age and older that included 8,931 COMIRNATY recipients and 8,895 placebo recipients, unsolicited adverse events were reported by 2,551 (28.6%) participants in the COMIRNATY group and 1,432 (16.1%) participants in the placebo group. Among participants with confirmed stable HIV infection that included 100 COMIRNATY recipients and 100 placebo recipients, unsolicited adverse events were reported by 29 (29%) participants in the COMIRNATY group and 15 (15%) participants in the placebo group. The higher frequency of reported unsolicited adverse events among COMIRNATY recipients compared with placebo recipients was primarily attributed to events that are consistent with adverse reactions solicited among participants in the reactogenicity subset (Table 5 and Table 6).

Throughout the placebo-controlled safety follow-up period, Bell's palsy (facial paralysis) was reported by 4 participants in the COMIRNATY group and 2 participants in the placebo group. Onset of facial paralysis was Day 37 after Dose 1 (participant did not receive Dose 2) and Days 3, 9, and 48 after Dose 2. In the placebo group the onset of facial paralysis was Day 32 and Day 102. Currently available information is insufficient to determine a causal relationship with the vaccine. In the analysis of blinded, placebo-controlled follow-up, there

were no other notable patterns or numerical imbalances between treatment groups for specific categories of non-serious adverse events (including other neurologic or neuro-inflammatory, and thrombotic events) that would suggest a causal relationship to COMIRNATY. In the analysis of unblinded follow-up, there were no notable patterns of specific categories of non-serious adverse events that would suggest a causal relationship to COMIRNATY.

#### Serious Adverse Events

Participants 16 through 55 years of age in Study 2 who had received at least 1 dose of vaccine or placebo (COMIRNATY = 12,995; placebo = 13,026), reported serious adverse events from Dose 1 up to the participant unblinding date in ongoing follow-up as follows: 103 (0.8%) COMIRNATY recipients and 117 (0.9%) placebo recipients. In a similar analysis, in participants 56 years of age and older (8,931 COMIRNATY group and 8,895 placebo group), serious adverse events were reported by 165 (1.8%) COMIRNATY recipients and 151 (1.7%) placebo recipients who received at least 1 dose of COMIRNATY or placebo, respectively. In these analyses, 58.2% of study participants had at least 4 months of follow-up after Dose 2. Among participants with confirmed stable HIV infection serious adverse events from Dose 1 up to the participant unblinding date in ongoing follow-up were reported by 2 (2%) COMIRNATY recipients and 2 (2%) placebo recipients.

In the analysis of blinded, placebo-controlled follow-up, there were no notable patterns between treatment groups for specific categories of serious adverse events (including neurologic, neuro-inflammatory, and thrombotic events) that would suggest a causal relationship to COMIRNATY. In the analysis of unblinded follow-up, there were no notable patterns of specific categories of serious adverse events that would suggest a causal relationship to COMIRNATY.

#### *Two-Dose Series (Original Monovalent) in Vaccine-Naïve Adolescents 12 Through 15 Years of Age*

Study 2 was a Phase 1/2/3 multicenter, randomized, saline placebo-controlled, double-blinded (Phase 2/3), dose-finding, vaccine candidate-selection and efficacy study. In Study 2, 2,260 adolescents (1,131 COMIRNATY; 1,129 placebo) were 12 through 15 years of age. At the time of the analysis of the ongoing Study 2 with a data cutoff of September 2, 2021, there were 1,559 (69.0%) adolescents (786 COMIRNATY and 773 placebo) 12 through 15 years of age followed for  $\geq 4$  months after the second dose.

Demographic characteristics in Study 2 were generally similar with regard to age, sex, race, and ethnicity among adolescents who received COMIRNATY and those who received placebo. Overall, among the adolescents who received COMIRNATY, 50.1% were male and 49.9% were female, 85.8% were White, 4.6% were Black or African American, 11.7% were Hispanic/Latino, 6.4% were Asian, and 0.4% were American Indian/Alaska Native.

In Study 2, participants 12 through 15 years of age in the reactogenicity subset were monitored using an electronic diary for solicited local and systemic reactions and use of antipyretic medication after each vaccination. Participants were also monitored for unsolicited adverse events throughout the study (from Dose 1 through 1 month [all unsolicited adverse events] or through 6 months [serious adverse events] after the last vaccination). Table 7 and Table 8 present the frequency and severity of solicited local and systemic reactions, respectively, within 7 days following Dose 1 or Dose 2 of COMIRNATY.

#### Local and Systemic Solicited Adverse Reactions

In adolescents 12 through 15 years of age after receiving Dose 2, the mean duration of pain at the injection site was 2.5 days (range 1 to 11 days), for redness 1.8 days (range 1 to 5 days), and for swelling 1.6 days (range 1 to 5 days) in the COMIRNATY group.

**Table 7: Study 2 – Frequency and Percentages of Adolescents With Solicited Local Reactions, by Maximum Severity, Within 7 Days After Each Dose – Adolescents 12 Through 15 Years of Age – Safety Population\***

	<b>COMIRNATY<sup>†</sup> Dose 1 N<sup>a</sup>=1127 n<sup>b</sup> (%)</b>	<b>Placebo Dose 1 N<sup>a</sup>=1127 n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>†</sup> Dose 2 N<sup>a</sup>=1097 n<sup>b</sup> (%)</b>	<b>Placebo Dose 2 N<sup>a</sup>=1078 n<sup>b</sup> (%)</b>
<b>Redness<sup>c</sup></b>				
Any (>2 cm)	65 (5.8)	12 (1.1)	55 (5.0)	10 (0.9)
Mild	44 (3.9)	11 (1.0)	29 (2.6)	8 (0.7)
Moderate	20 (1.8)	1 (0.1)	26 (2.4)	2 (0.2)
Severe	1 (0.1)	0 (0.0)	0 (0.0)	0 (0.0)
<b>Swelling<sup>c</sup></b>				
Any (>2 cm)	78 (6.9)	11 (1.0)	54 (4.9)	6 (0.6)
Mild	55 (4.9)	9 (0.8)	36 (3.3)	4 (0.4)
Moderate	23 (2.0)	2 (0.2)	18 (1.6)	2 (0.2)
Severe	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
<b>Pain at the injection site<sup>d</sup></b>				
Any	971 (86.2)	263 (23.3)	866 (78.9)	193 (17.9)
Mild	467 (41.4)	227 (20.1)	466 (42.5)	164 (15.2)
Moderate	493 (43.7)	36 (3.2)	393 (35.8)	29 (2.7)
Severe	11 (1.0)	0 (0.0)	7 (0.6)	0 (0.0)

Note: Reactions were collected in the electronic diary (e-diary) from Day 1 to Day 7 after vaccination.

\* Randomized participants in the safety analysis population who received at least 1 dose of the study intervention.

† Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose.

b. n = Number of participants with the specified reaction.

c. Mild: >2.0 to ≤5.0 cm; Moderate: >5.0 to ≤10.0 cm; Severe: >10.0 cm.

d. Mild: does not interfere with activity; Moderate: interferes with activity; Severe: prevents daily activity.

**Table 8: Study 2 – Frequency and Percentages of Adolescents With Solicited Systemic Reactions, by Maximum Severity, Within 7 Days After Each Dose – Adolescents 12 Through 15 Years of Age – Safety Population\***

	<b>COMIRNATY<sup>†</sup> Dose 1 N<sup>a</sup>=1127 n<sup>b</sup> (%)</b>	<b>Placebo Dose 1 N<sup>a</sup>=1127 n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>†</sup> Dose 2 N<sup>a</sup>=1097 n<sup>b</sup> (%)</b>	<b>Placebo Dose 2 N<sup>a</sup>=1078 n<sup>b</sup> (%)</b>
<b>Fever</b>				
≥38.0°C	114 (10.1)	12 (1.1)	215 (19.6)	7 (0.6)
≥38.0°C to 38.4°C	74 (6.6)	8 (0.7)	107 (9.8)	5 (0.5)
>38.4°C to 38.9°C	29 (2.6)	2 (0.2)	83 (7.6)	1 (0.1)
>38.9°C to 40.0°C	10 (0.9)	2 (0.2)	25 (2.3)	1 (0.1)
>40.0°C	1 (0.1)	0 (0.0)	0 (0.0)	0 (0.0)
<b>Fatigue<sup>c</sup></b>				
Any	677 (60.1)	457 (40.6)	726 (66.2)	264 (24.5)
Mild	278 (24.7)	250 (22.2)	232 (21.1)	133 (12.3)
Moderate	384 (34.1)	199 (17.7)	468 (42.7)	127 (11.8)
Severe	15 (1.3)	8 (0.7)	26 (2.4)	4 (0.4)

	<b>COMIRNATY<sup>†</sup> Dose 1 N<sup>a</sup>=1127 n<sup>b</sup> (%)</b>	<b>Placebo Dose 1 N<sup>a</sup>=1127 n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>†</sup> Dose 2 N<sup>a</sup>=1097 n<sup>b</sup> (%)</b>	<b>Placebo Dose 2 N<sup>a</sup>=1078 n<sup>b</sup> (%)</b>
<b>Headache<sup>c</sup></b>				
Any	623 (55.3)	396 (35.1)	708 (64.5)	264 (24.5)
Mild	361 (32.0)	256 (22.7)	302 (27.5)	170 (15.8)
Moderate	251 (22.3)	131 (11.6)	384 (35.0)	93 (8.6)
Severe	11 (1.0)	9 (0.8)	22 (2.0)	1 (0.1)
<b>Chills<sup>c</sup></b>				
Any	311 (27.6)	109 (9.7)	455 (41.5)	74 (6.9)
Mild	195 (17.3)	82 (7.3)	221 (20.1)	53 (4.9)
Moderate	111 (9.8)	25 (2.2)	214 (19.5)	21 (1.9)
Severe	5 (0.4)	2 (0.2)	20 (1.8)	0 (0.0)
<b>Vomiting<sup>d</sup></b>				
Any	31 (2.8)	10 (0.9)	29 (2.6)	12 (1.1)
Mild	30 (2.7)	8 (0.7)	25 (2.3)	11 (1.0)
Moderate	0 (0.0)	2 (0.2)	4 (0.4)	1 (0.1)
Severe	1 (0.1)	0 (0.0)	0 (0.0)	0 (0.0)
<b>Diarrhea<sup>e</sup></b>				
Any	90 (8.0)	82 (7.3)	65 (5.9)	44 (4.1)
Mild	77 (6.8)	72 (6.4)	59 (5.4)	39 (3.6)
Moderate	13 (1.2)	10 (0.9)	6 (0.5)	5 (0.5)
Severe	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
<b>New or worsened muscle pain<sup>c</sup></b>				
Any	272 (24.1)	148 (13.1)	355 (32.4)	90 (8.3)
Mild	125 (11.1)	88 (7.8)	152 (13.9)	51 (4.7)
Moderate	145 (12.9)	60 (5.3)	197 (18.0)	37 (3.4)
Severe	2 (0.2)	0 (0.0)	6 (0.5)	2 (0.2)
<b>New or worsened joint pain<sup>c</sup></b>				
Any	109 (9.7)	77 (6.8)	173 (15.8)	51 (4.7)
Mild	66 (5.9)	50 (4.4)	91 (8.3)	30 (2.8)
Moderate	42 (3.7)	27 (2.4)	78 (7.1)	21 (1.9)
Severe	1 (0.1)	0 (0.0)	4 (0.4)	0 (0.0)
<b>Use of antipyretic or pain medication<sup>f</sup></b>				
	413 (36.6)	111 (9.8)	557 (50.8)	95 (8.8)

Note: Events and use of antipyretic or pain medication were collected in the electronic diary (e-diary) from Day 1 to Day 7 after each dose.

\* Randomized participants in the safety analysis population who received at least 1 dose of the study intervention.

† Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants reporting at least 1 yes or no response for the specified event after the specified dose.

b. n = Number of participants with the specified reaction.

c. Mild: does not interfere with activity; Moderate: some interference with activity; Severe: prevents daily activity.

d. Mild: 1 to 2 times in 24 hours; Moderate: >2 times in 24 hours; Severe: requires intravenous hydration.

e. Mild: 2 to 3 loose stools in 24 hours; Moderate: 4 to 5 loose stools in 24 hours; Severe: 6 or more loose stools in 24 hours.

f. Severity was not collected for use of antipyretic or pain medication.

### Unsolicited Adverse Events

In Study 2, 2,260 adolescents (1,131 COMIRNATY; 1,129 placebo) were 12 through 15 years of age. Of these, 634 (56.1%) participants in the COMIRNATY group and 629 (55.7%) participants in the placebo group had

follow-up time between  $\geq 4$  months to  $< 6$  months after Dose 2 in the blinded placebo-controlled follow-up period with an additional 152 (13.4%) and 144 (12.8%) with  $\geq 6$  months of blinded follow-up time in the COMIRNATY and placebo groups, respectively.

A total of 1,113 (98.4%) participants 12 through 15 years of age originally randomized to COMIRNATY had  $\geq 6$  months total (blinded and unblinded) follow-up after Dose 2. An analysis of all unsolicited adverse events in Study 2 from Dose 1 up to the participant unblinding date was conducted. Among participants 12 through 15 years of age who received at least 1 dose of study vaccine, unsolicited adverse events were reported by 95 (8.4%) participants in the COMIRNATY group and 113 (10.0%) participants in the placebo group.

In an analysis of all unsolicited adverse events reported during blinded follow-up from Dose 1 through 1 month after Dose 2, in adolescents 12 to 15 years of age, those assessed as adverse reactions not already captured by solicited local and systemic reactions were lymphadenopathy (9 vs. 2), and nausea (5 vs. 2).

In the analysis of blinded, placebo-controlled follow-up, there were no other notable patterns or numerical imbalances between treatment groups for specific categories of unsolicited adverse events (including other neurologic or neuro-inflammatory, and thrombotic events) that would suggest a causal relationship to COMIRNATY. In the analysis of unblinded follow-up, there were no notable patterns of specific categories of non-serious adverse events that would suggest a causal relationship to COMIRNATY.

#### Serious Adverse Events

In Study 2, among participants 12 through 15 years of age who had received at least 1 dose of vaccine or placebo (COMIRNATY = 1,131; placebo = 1,129), serious adverse events from Dose 1 up to the participant unblinding date in ongoing follow-up were reported by 10 (0.9%) COMIRNATY recipients and 2 (0.2%) placebo recipients. In these analyses, 69.0% of study participants had at least 4 months of follow-up after Dose 2. In the analysis of blinded, placebo-controlled follow-up, there were no notable patterns between treatment groups for specific categories of serious adverse events (including neurologic, neuro-inflammatory, and thrombotic events) that would suggest a causal relationship to COMIRNATY. In the analysis of unblinded follow-up, there were no notable patterns of specific categories of serious adverse events that would suggest a causal relationship to COMIRNATY.

#### *Single Dose (Original Monovalent) in Vaccine-Experienced Individuals 12 Years of Age and Older*

##### 16 Years of Age and Older

In Study 4, a double-blind placebo-controlled booster study, 5,081 participants 16 years of age and older recruited from Study 2 received a booster dose of COMIRNATY 10.8 months (median time, range of 5.0 to 12.6 months) after completing the primary series of COMIRNATY series and had a median follow-up time of 2.9 months based on data up to the cutoff date of February 8, 2022. The median age of participants who received COMIRNATY or placebo was 53.0 years (range 16 through 87 years of age), 49.1% were male and 50.9% were female, 79.0% were White, 14.9% were Hispanic/Latino, 9.2% were Black or African American, 5.5% were Asian, and 1.7% were American Indian/Alaska Native.

Adverse reactions reported in participants receiving a booster dose of COMIRNATY were similar to those previously observed in participants receiving COMIRNATY as part of the primary series. Lymphadenopathy occurred in 141 (2.8%) participants who received a booster dose of COMIRNATY and in 83 (0.4%) participants who received COMIRNATY as a primary series.

### 18 Years Through 55 Years of Age

A subset of 306 Study 2 Phase 2/3 participants 18 through 55 years of age received a booster dose of COMIRNATY 6.8 months (median time, range 4.8 to 8.0 months) after completing the primary series. These participants had a median follow-up time of 8.3 months up to a data cutoff date of November 22, 2021. Among the 306 participants, the median age was 42 years (range 19 through 55 years of age), 45.8% were male and 54.2% were female, 81.4% were White, 27.8% were Hispanic/Latino, 9.2% were Black or African American, 5.2% were Asian, and 0.7% were American Indian/Alaska Native.

Adverse reactions reported in participants receiving a booster dose of COMIRNATY were similar to those previously observed in participants receiving COMIRNATY as part of the primary series. Lymphadenopathy occurred in 16 (5.2%) of participants who received a booster dose of COMIRNATY and 83 (0.4%) in participants who received COMIRNATY as a primary series.

### 12 Years Through 17 Years of Age

A subset of 65 Study 4 participants 12 through 17 years of age received a booster dose of COMIRNATY 13.3 months (median time, range 6.5 to 16.9 months) after completing the primary series and had a median follow-up time of 5.6 months up to a data cutoff date of July 14, 2022. The median age of participants was 14 years (range 12 through 17 years of age), 49.2% were male and 50.8% were female, 76.9% were White, 16.9% were Hispanic/Latino, 13.8% were Black or African American, 7.7% were Asian, and 1.5% were American Indian/Alaska Native.

Adverse reactions reported in participants receiving a booster dose of COMIRNATY were similar to those previously observed in participants receiving COMIRNATY as part of the primary series. There were no cases of lymphadenopathy reported in participants who received a booster dose of COMIRNATY.

### 12 Years Through 15 Years of Age

A subset of 825 Study 2 Phase 2/3 participants 12 through 15 years of age received a booster dose of COMIRNATY 11.2 months (median time, range 6.3 to 20.1 months) after completing the primary series and had a median follow-up time of 9.5 months up to a data cutoff date of November 3, 2022. The median age of participants was 14.0 years (range 13 through 15 years of age), 49.3% were male and 50.7% were female, 83.5% were White, 10.8% were Hispanic/Latino, 4.6% were Black or African American, 7.5% were Asian, and 0.4% were American Indian/Alaska Native.

Adverse reactions reported in participants receiving a booster dose of COMIRNATY were similar to those previously observed in participants receiving COMIRNATY as part of the primary series. Lymphadenopathy occurred in 8 (1.0%) participants who received a booster dose of COMIRNATY and in 9 (0.8%) participants who received COMIRNATY as a primary series.

### Single Dose (Bivalent Original and BA.4/BA.5) in Vaccine-Experienced Individuals 12 Years of Age and Older

A subset of 107 Study 5 Phase 2/3 participants 12 through 17 years of age, 313 participants 18 through 55 years of age and 306 participants 56 years of age and older previously vaccinated with a 2-dose primary series and 1 booster dose of COMIRNATY, went on to receive a second booster dose with Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

Participants received a second booster dose 11.1 months (median time; range 5.4 to 16.9 months) after receiving the first booster dose and had a median follow-up time of 1.5 months up to a data cutoff date of October 31, 2022. The median age was 48.0 years, 42.7% were male, 57.3% were female, 80.6% were White, 11.4% were Hispanic/Latino, 5.9% were Asian, and 11.4% were Black or African American.

Local and Systemic Solicited Adverse Reactions

Table 9 and Table 10 present the frequency and severity of reported solicited local reactions and systemic reactions, respectively, within 7 days of a second booster dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

In participants 12 years of age and older who received a second booster dose, the mean duration of injection site pain was 2.1 to 2.4 days (range 1 to 11 days), injection site redness was 1.5 to 2.5 days (range 1 to 4 days), and injection site swelling was 1.3 to 1.9 days (range 1 to 4 days), respectively.

**Table 9: Study 5 – Frequency and Percentages of Participants With Solicited Local Reactions, by Maximum Severity, Within 7 Days After a Second Booster Dose – Participants 12 Years of Age and Older – Safety Population**

	Pfizer-BioNTech COVID-19 Vaccine, Bivalent*		
	12 Through 17 Years of Age N <sup>a</sup> =107 n <sup>b</sup> (%)	18 Through 55 Years of Age N <sup>a</sup> =309 <sup>†</sup> n <sup>b</sup> (%)	56 Years of Age and Older N <sup>a</sup> =300 <sup>†</sup> n <sup>b</sup> (%)
<b>Redness<sup>c</sup></b>			
Any (>2 cm)	6 (5.6)	21 (6.8%)	11 (3.7%)
Mild	4 (3.7)	16 (5.2%)	7 (2.3)
Moderate	2 (1.9)	5 (1.6)	4 (1.3%)
Severe	0	0	0
<b>Swelling<sup>c</sup></b>			
Any (>2 cm)	8 (7.5)	23 (7.4%)	8 (2.7)
Mild	6 (5.6)	19 (6.1%)	5 (1.7)
Moderate	2 (1.9)	4 (1.3)	3 (1.0)
Severe	0	0	0
<b>Pain at the injection site<sup>d</sup></b>			
Any	75 (70.1)	236 (76.1)	172 (57.1)
Mild	45 (42.1)	178 (57.4)	147 (48.8)
Moderate	29 (27.1)	58 (18.7)	24 (8.0)
Severe	1 (0.9)	0	1 (0.3)

Note: Adverse Reactions were collected in the electronic diary (e-diary) from day of vaccination (Day 1) through Day 7 after the study vaccination.

\* Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original) and Omicron variant lineages BA.4 and BA.5 (Omicron BA.4/BA.5).

† N = 310 for redness and pain at injection site in participants 18 through 55 years of age; N = 301 for pain at injection site in participants 56 years of age and older.

a. N = Number of participants reporting at least 1 yes or no response for the specified reaction after the study vaccination.

b. n = Number of participants with the specified adverse reaction.

c. Mild: >2.0 to 5.0 cm; Moderate: >5.0 to 10.0 cm; Severe: >10.0 cm.

d. Mild: does not interfere with activity; Moderate: interferes with activity; Severe: prevents daily activity.

**Table 10: Study 5 – Frequency and Percentages of Participants With Solicited Systemic Adverse Reactions, by Maximum Severity, Within 7 Days After a Second Booster Dose – Participants 12 Years of Age and Older – Safety Population**

	Pfizer-BioNTech COVID-19 Vaccine, Bivalent*		
	12 Through 17 Years of Age N <sup>a</sup> =107 n <sup>b</sup> (%)	18 Through 55 Years of Age N <sup>a</sup> =309 n <sup>b</sup> (%)	56 Years of Age and Older N <sup>a</sup> =300 <sup>†</sup> n <sup>b</sup> (%)
<b>Fever</b>			
≥38.0°C	10 (9.3)	15 (4.9)	14 (4.7)
≥38.0°C to 38.4°C	7 (6.5)	9 (2.9)	10 (3.3)
>38.4°C to 38.9°C	2 (1.9)	6 (1.9)	3 (1.0)
>38.9°C to 40.0°C	1 (0.9)	0	0
>40.0°C	0	0	0
<b>Fatigue<sup>c</sup></b>			
Any	72 (67.3)	189 (61.2)	116 (38.5)
Mild	27 (25.2)	83 (26.9)	56 (18.6)
Moderate	45 (42.1)	100 (32.4)	56 (18.6)
Severe	0	6 (1.9)	4 (1.3)
<b>Headache<sup>c</sup></b>			
Any	54 (50.5)	144 (46.6)	92 (30.7)
Mild	28 (26.2)	87 (28.2)	62 (20.7)
Moderate	26 (24.3)	55 (17.8)	30 (10.0)
Severe	0	2 (0.6)	0
<b>Chills<sup>c</sup></b>			
Any	25 (23.4)	68 (22.0)	36 (12.0)
Mild	19 (17.8)	38 (12.3)	21 (7.0)
Moderate	6 (5.6)	28 (9.1)	14 (4.7)
Severe	0	2 (0.6)	1 (0.3)
<b>Vomiting<sup>d</sup></b>			
Any	3 (2.8)	6 (1.9)	2 (0.7)
Mild	3 (2.8)	5 (1.6)	2 (0.7)
Moderate	0	1 (0.3)	0
Severe	0	0	0
<b>Diarrhea<sup>e</sup></b>			
Any	7 (6.5)	33 (10.7)	29 (9.6)
Mild	7 (6.5)	27 (8.7)	23 (7.6)
Moderate	0	5 (1.6)	6 (2.0)
Severe	0	1 (0.3)	0
<b>New or worsened muscle pain<sup>c</sup></b>			
Any	28 (26.2)	94 (30.4)	54 (18.0)
Mild	12 (11.2)	47 (15.2)	30 (10.0)
Moderate	16 (15.0)	47 (15.2)	24 (8.0)
Severe	0	0	0

	Pfizer-BioNTech COVID-19 Vaccine, Bivalent*		
	12 Through 17 Years of Age N <sup>a</sup> =107 n <sup>b</sup> (%)	18 Through 55 Years of Age N <sup>a</sup> =309 n <sup>b</sup> (%)	56 Years of Age and Older N <sup>a</sup> =300 <sup>†</sup> n <sup>b</sup> (%)
New or worsened joint pain <sup>c</sup>			
Any	13 (12.1)	46 (14.9)	36 (12.0)
Mild	9 (8.4)	21 (6.8)	20 (6.7)
Moderate	4 (3.7)	25 (8.1)	16 (5.3)
Severe	0	0	0
Use of antipyretic or pain medication <sup>f</sup>	36 (33.6)	105 (34.0)	74 (24.7)

Note: Adverse reactions and use of antipyretic or pain medication were collected in the electronic diary (e-diary) from day of vaccination (Day 1) through Day 7 after the study vaccination.

\* Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original) and Omicron variant lineages BA.4 and BA.5 (Omicron BA.4/BA.5).

† N = 301 for fever, fatigue and diarrhea in participants 56 years of age and older.

a. N = Number of participants reporting at least 1 yes or no response for the specified adverse reaction after the study vaccination.

b. n = Number of participants with the specified adverse reaction.

c. Mild: does not interfere with activity; Moderate: some interference with activity; Severe: prevents daily activity.

d. Mild: 1 to 2 times in 24 hours; Moderate: >2 times in 24 hours; Severe: requires intravenous hydration.

e. Mild: 2 to 3 loose stools in 24 hours; Moderate: 4 to 5 loose stools in 24 hours; Severe: 6 or more loose stools in 24 hours.

f. Severity was not collected for use of antipyretic or pain medication.

### Unsolicited Adverse Events

Among participants 12 years of age and older, unsolicited adverse events were reported by 48 (6.6%) participants who received a second booster dose through 1 month after the booster dose. Lymphadenopathy occurred in 7 (1.0%) participants.

### *Concomitant Administration of COMIRNATY (Original Monovalent) With Influenza Vaccine in Adults 18 Years Through 64 Years of Age*

In Study 8, a Phase 3 study, participants 18 through 64 years of age who received COMIRNATY concomitantly administered with Influenza Vaccine (Afluria Quadrivalent) followed 1 month later by saline placebo (n = 564) were compared with participants who received influenza vaccine with saline placebo followed 1 month later by COMIRNATY (n = 564).

Demographic characteristics in Study 8 among the participants in the concomitant administration and separate administration groups were similar with regard to age, sex, race, and ethnicity. Among the 564 participants in the concomitant administration group, the median age was 39.0 years (range 18 through 64 years of age), 36.9% were male and 63.1% were female, 79.1% were White, 12.9% were Asian, and 0.9% were Hispanic/Latino.

Solicited local and systemic adverse reactions were reported more frequently by participants who received COMIRNATY concomitantly with influenza vaccine, compared with participants who received COMIRNATY alone. The most common adverse reactions reported in the concomitant administration group and after COMIRNATY alone were injection site pain (COMIRNATY injection site) (86.2% and 84.4%, respectively), fatigue (64.0% and 50.8%, respectively), and headache (47.2% and 37.8%, respectively).

## Children 5 Years Through 11 Years of Age

### *Two-Dose Series (Original Monovalent) in Vaccine-Naïve Children 5 Years Through 11 Years of Age*

Study 3 is a Phase 1/2/3 multicenter, randomized, dose-finding, open label (Phase 1) and multinational, placebo controlled (saline placebo), observer-blind, immunogenicity and efficacy (Phase 2/3) study that has evaluated 4,695 participants 5 through 11 years of age, of whom 3,109 participants received COMIRNATY and 1,538 participants received placebo in Phase 2/3.

Demographic characteristics were generally similar with regard to age, sex, race, and ethnicity among participants who received COMIRNATY and those who received placebo. Overall, among the 4,647 participants who received at least 1 dose of COMIRNATY or placebo, 51.4% were male and 48.6% were female, 77.5% were White, 6.0% were Black or African American, 17.0% were Hispanic/Latino, 8.1% were Asian, and 0.4% were American Indian/Alaska Native.

In an analysis of Study 3 (Phase 2/3), 4,632 participants 5 through 11 years of age who received a 2-dose primary series [3,100 COMIRNATY; 1,532 placebo] have been followed a median of 1.9 months (range 0.1 to 7.5 months) after the second dose in the blinded placebo-controlled follow-up period up to the cutoff date of May 20, 2022.

In Study 3, participants 5 years through 11 years of age in the reactogenicity subset were monitored using an electronic diary for solicited local and systemic adverse reactions and use of antipyretic medication after each vaccination. Participants were also monitored for unsolicited adverse events throughout the study (from Dose 1 through 1 month [all unsolicited adverse events] or through 6 months [serious adverse events] after the last vaccination). Table 11 and Table 12 present the frequency and severity of solicited local and systemic reactions, respectively, within 7 days following Dose 1 or Dose 2 of COMIRNATY.

#### Solicited Local and Systemic Adverse Reactions

The mean duration of pain at the injection site after Dose 2 was 2.3 days (range 1 to 37 days), for redness 2.0 days (range 1 to 10 days), and for swelling 2.2 days (range 1 to 16 days) for children in the COMIRNATY group in the blinded placebo-controlled follow-up period up to the cutoff date of May 20, 2022.

**Table 11: Study 3 – Frequency and Percentages of Participants With Solicited Local Reactions, by Maximum Severity, Within 7 Days After Each Dose – Children 5 Through 11 Years of Age – Safety Population\***

	<b>COMIRNATY<sup>±</sup> Dose 1 N<sup>a</sup>=3096 n<sup>b</sup> (%)</b>	<b>Placebo Dose 1 N<sup>a</sup>=1531 to 1532 n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>±</sup> Dose 2 N<sup>a</sup>=3064 n<sup>b</sup> (%)</b>	<b>Placebo Dose 2 N<sup>a</sup>=1521 to 1522 n<sup>b</sup> (%)</b>
<b>Redness<sup>c</sup></b>				
Any (≥0.5 cm)	434 (14.0)	91 (5.9)	575 (18.8)	79 (5.2)
Mild	287 (9.3)	78 (5.1)	315 (10.3)	57 (3.7)
Moderate	146 (4.7)	11 (0.7)	257 (8.4)	20 (1.3)
Severe	1 (0.0)	2 (0.1)	3 (0.1)	2 (0.1)
<b>Swelling<sup>c</sup></b>				
Any (≥0.5 cm)	320 (10.3)	46 (3.0)	450 (14.7)	41 (2.7)
Mild	177 (5.7)	28 (1.8)	247 (8.1)	30 (2.0)
Moderate	142 (4.6)	18 (1.2)	203 (6.6)	11 (0.7)
Severe	1 (0.0)	0	0	0

	<b>COMIRNATY<sup>±</sup></b> <b>Dose 1</b> <b>N<sup>a</sup>=3096</b> <b>n<sup>b</sup> (%)</b>	<b>Placebo</b> <b>Dose 1</b> <b>N<sup>a</sup>=1531 to 1532</b> <b>n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>±</sup></b> <b>Dose 2</b> <b>N<sup>a</sup>=3064</b> <b>n<sup>b</sup> (%)</b>	<b>Placebo</b> <b>Dose 2</b> <b>N<sup>a</sup>=1521 to 1522</b> <b>n<sup>b</sup> (%)</b>
<b>Pain at the injection site<sup>d</sup></b>				
Any	2258 (72.9)	482 (31.5)	2181 (71.2)	434 (28.5)
Mild	1810 (58.5)	434 (28.3)	1642 (53.6)	389 (25.6)
Moderate	442 (14.3)	48 (3.1)	533 (17.4)	44 (2.9)
Severe	6 (0.2)	0	6 (0.2)	1 (0.1)

Note: Reactions were collected in an electronic diary (e-diary) from Day 1 to Day 7 after vaccination.

a. N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose.

b. n = Number of participants with the specified reaction.

c. Mild:  $\geq 0.5$  to  $< 2.0$  cm; Moderate:  $> 2.0$  to  $< 7.0$  cm; Severe:  $> 7.0$  cm.

d. Mild: does not interfere with activity; Moderate: interferes with activity; Severe: prevents daily activity.

\* Randomized participants who received at least 1 dose of the study intervention.

± Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

**Table 12: Study 3 – Frequency and Percentages of Participants With Solicited Systemic Reactions, by Maximum Severity, Within 7 Days After Each Dose – Children 5 Through 11 Years of Age – Safety Population\***

	<b>COMIRNATY<sup>±</sup></b> <b>Dose 1</b> <b>N<sup>a</sup>=3096</b> <b>n<sup>b</sup> (%)</b>	<b>Placebo</b> <b>Dose 1</b> <b>N<sup>a</sup>=1531 to 1532</b> <b>n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>±</sup></b> <b>Dose 2</b> <b>N<sup>a</sup>=3064</b> <b>n<sup>b</sup> (%)</b>	<b>Placebo</b> <b>Dose 2</b> <b>N<sup>a</sup>=1521 to 1522</b> <b>n<sup>b</sup> (%)</b>
<b>Fever</b>				
$\geq 38.0^{\circ}\text{C}$	64 (2.1)	21 (1.4)	193 (6.3)	21 (1.4)
$\geq 38.0^{\circ}\text{C}$ to $38.4^{\circ}\text{C}$	37 (1.2)	10 (0.7)	101 (3.3)	13 (0.9)
$> 38.4^{\circ}\text{C}$ to $38.9^{\circ}\text{C}$	22 (0.7)	9 (0.6)	70 (2.3)	5 (0.3)
$> 38.9^{\circ}\text{C}$ to $40.0^{\circ}\text{C}$	4 (0.1)	2 (0.1)	21 (0.7)	3 (0.2)
$> 40.0^{\circ}\text{C}$	1 (0.0)	0	1 (0.0)	0
<b>Fatigue<sup>c</sup></b>				
Any	1067 (34.5)	496 (32.4)	1200 (39.2)	383 (25.2)
Mild	702 (22.7)	323 (21.1)	665 (21.7)	230 (15.1)
Moderate	360 (11.6)	171 (11.2)	508 (16.6)	149 (9.8)
Severe	5 (0.2)	2 (0.1)	27 (0.9)	4 (0.3)
<b>Headache<sup>c</sup></b>				
Any	703 (22.7)	372 (24.3)	870 (28.4)	284 (18.7)
Mild	530 (17.1)	275 (18.0)	576 (18.8)	201 (13.2)
Moderate	170 (5.5)	91 (5.9)	286 (9.3)	82 (5.4)
Severe	3 (0.1)	6 (0.4)	8 (0.3)	1 (0.1)

	<b>COMIRNATY<sup>±</sup> Dose 1 N<sup>a</sup>=3096 n<sup>b</sup> (%)</b>	<b>Placebo Dose 1 N<sup>a</sup>=1531 to 1532 n<sup>b</sup> (%)</b>	<b>COMIRNATY<sup>±</sup> Dose 2 N<sup>a</sup>=3064 n<sup>b</sup> (%)</b>	<b>Placebo Dose 2 N<sup>a</sup>=1521 to 1522 n<sup>b</sup> (%)</b>
<b>Chills<sup>c</sup></b>				
Any	174 (5.6)	84 (5.5)	301 (9.8)	66 (4.3)
Mild	138 (4.5)	69 (4.5)	205 (6.7)	52 (3.4)
Moderate	36 (1.2)	15 (1.0)	94 (3.1)	13 (0.9)
Severe	0	0	2 (0.1)	1 (0.1)
<b>Vomiting<sup>d</sup></b>				
Any	63 (2.0)	30 (2.0)	62 (2.0)	27 (1.8)
Mild	52 (1.7)	28 (1.8)	56 (1.8)	22 (1.4)
Moderate	11 (0.4)	2 (0.1)	5 (0.2)	5 (0.3)
Severe	0	0	1 (0.0)	0
<b>Diarrhea<sup>e</sup></b>				
Any	198 (6.4)	75 (4.9)	166 (5.4)	76 (5.0)
Mild	184 (5.9)	72 (4.7)	149 (4.9)	70 (4.6)
Moderate	14 (0.5)	3 (0.2)	15 (0.5)	6 (0.4)
Severe	0	0	2 (0.1)	0
<b>New or worsened muscle pain<sup>c</sup></b>				
Any	289 (9.3)	126 (8.2)	368 (12.0)	104 (6.8)
Mild	206 (6.7)	96 (6.3)	245 (8.0)	68 (4.5)
Moderate	82 (2.6)	30 (2.0)	122 (4.0)	36 (2.4)
Severe	1 (0.0)	0	1 (0.0)	0
<b>New or worsened joint pain<sup>c</sup></b>				
Any	106 (3.4)	70 (4.6)	159 (5.2)	57 (3.7)
Mild	71 (2.3)	56 (3.7)	103 (3.4)	42 (2.8)
Moderate	35 (1.1)	14 (0.9)	56 (1.8)	15 (1.0)
Severe	0	0	0	0
<b>Use of antipyretic or pain medication<sup>f</sup></b>				
	436 (14.1)	135 (8.8)	601 (19.6)	111 (7.3)

Note: Events and use of antipyretic or pain medication were collected in an electronic diary (e-diary) from Day 1 to Day 7 after each dose.

a. N = Number of participants reporting at least 1 yes or no response for the specified event after the specified dose.

b. n = Number of participants with the specified reaction.

c. Mild: does not interfere with activity; Moderate: some interference with activity; Severe: prevents daily activity.

d. Mild: 1 to 2 times in 24 hours; Moderate: >2 times in 24 hours; Severe: requires intravenous hydration.

e. Mild: 2 to 3 loose stools in 24 hours; Moderate: 4 to 5 loose stools in 24 hours; Severe: 6 or more loose stools in 24 hours.

f. Severity was not collected for use of antipyretic or pain medication.

\* Randomized participants who received at least 1 dose of the study intervention.

± Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

### Unsolicited Adverse Events

In the following analyses of Study 3 in participants 5 through 11 years of age, 3,109 participants received COMIRNATY and 1,538 participants received placebo. Among those who received 2 doses of COMIRNATY or placebo, 1,185 participants in the COMIRNATY group and 575 participants in the placebo group had follow-up time  $\geq 4$  to  $< 6$  months and 296 participants in the COMIRNATY group and 150 participants in the placebo group had follow-up time of  $> 6$  months in the blinded placebo-controlled follow-up period.

Among participants who received at least 1 dose of study vaccine, unsolicited adverse events were reported by 333 (10.7%) participants in the COMIRNATY group and 150 (9.8%) participants in the placebo group.

In an analysis of all unsolicited adverse events reported following administration of Dose 1 to one month after administration of Dose 2, the adverse reactions (excluding reactions reported as solicited adverse reactions) in participants who received COMIRNATY compared with participants who received placebo were lymphadenopathy (n=23; 0.7% vs. n=4; 0.3%), nausea (n=7; 0.2% vs. n=3; 0.2%), decreased appetite (n=3; 0.1% vs. n=2; 0.1%), malaise (n=2; 0.1% vs. n=0), and night sweats (n=1; 0.0% vs. n=0).

#### Serious Adverse Events

Serious adverse events, from administration of Dose 1 to the participant unblinding date, were reported in 8 (0.3%) COMIRNATY recipients and in 2 (0.1%) placebo recipients. No serious adverse events were considered related to vaccination.

#### *Single Dose (Original Monovalent) in Vaccine-Experienced Children 5 Years Through 11 Years of Age*

In Phase 2/3 of Study 3, 2,408 participants 5 years through 11 years of age received a first booster dose of COMIRNATY at a median of 7.9 months (range 5.3 to 19.4 months) after completing the primary series. These participants had a median safety follow-up of 6.4 months from vaccination through the data cutoff date of February 28, 2023. The median age was 8.0 years (range 5 through 11 years of age), 50.5% were male and 49.5% were female, 76.3% were White, 5.9% were Black or African American, 16.9% were Hispanic/Latino, 8.2% were Asian, and 0.5% were American Indian/Alaska Native.

#### Solicited Local and Systemic Adverse Reactions

The frequency of solicited adverse reactions reported in participants receiving a booster dose of COMIRNATY were generally consistent with those reported in pediatric participants receiving COMIRNATY as part of the two-dose series.

#### Unsolicited Adverse Events

Lymphadenopathy occurred in 46 (1.9%) participants who received a booster dose of COMIRNATY and in 23 (0.7%) participants who received COMIRNATY as a primary series.

#### Serious Adverse Events

Serious adverse events from study vaccination through 6 months after study vaccination were reported by 10 (0.4%) COMIRNATY recipients. No serious adverse events were considered related to vaccination.

#### *Single Dose (Bivalent Original and BA.4/BA.5) in Vaccine-Experienced Children 5 Years Through 11 Years of Age*

In Study 6, 113 participants 5 years through 11 years of age previously vaccinated with a 2-dose primary series and 1 booster dose of COMIRNATY received a second booster (fourth dose) with Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5). Participants received a second booster with Pfizer-BioNTech COVID-19, Bivalent 2.6 to 8.5 months after receiving their third dose with COMIRNATY and had a median follow-up time of 6.3 months (range 1.1 to 6.8 months) up to a data cutoff date of April 20, 2023. The median age of participants was 9 years (range 5 through 11 years of age), 50.4% were male and 49.6% were female, 58.4% were White, 20.4% were Hispanic/Latino, 19.5% were multiracial, 11.5% were Asian, and 8.0% were Black or African American.

#### Solicited Local and Systemic Adverse Reactions

The frequency of solicited adverse reactions reported in participants receiving a second booster dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and BA.4/BA.5) were generally consistent with those reported in pediatric participants receiving COMIRNATY.

#### Unsolicited Adverse Events

Lymphadenopathy was reported in 1 (0.9%) participant who received Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and BA.4/BA.5).

#### Serious Adverse Events

No serious adverse events were reported.

#### *Single Dose (Monovalent XBB.1.5) in Vaccine-Naïve Children 5 Years Through 11 Years of Age*

In a subset of Study 6, the safety of a single dose of COMIRNATY (encoding the viral spike (S) glycoprotein of SARS-CoV-2 Omicron XBB.1.5) was evaluated in 310 COVID-19 vaccine-naïve participants 5 through 11 years of age. Participants had a median follow-up time of 6.4 months (range 1.7 to 6.9 months). The median age of participants was 7.0 years (range 5 through 11 years of age), 47.1% were male and 52.9% were female, 41.3% were White, 52.9% were Black or African American, 52.3% were Hispanic or Latino, 1.9% were Asian, and 0.3% were American Indian/Alaska Native.

#### Solicited Local and Systemic Adverse Reactions

The frequency of solicited adverse reactions reported in participants who received a single dose of COMIRNATY, monovalent (XBB.1.5) were generally consistent with those previously reported by participants receiving COMIRNATY.

#### Unsolicited Adverse Events

In an analysis of all unsolicited adverse events through 1 month after study vaccination, unsolicited adverse events were reported by 11 (3.5%) COMIRNATY recipients. The adverse reaction not already captured by solicited local and systemic reactions was decreased appetite (n=1; 0.3%).

#### Serious Adverse Events

Serious adverse events from study vaccination through 6 months after study vaccination were reported by 3 (1.0%) COMIRNATY recipients. No serious adverse events were considered related to vaccination.

## **6.2 Postmarketing Experience**

The following adverse reactions have been identified during postmarketing use of COMIRNATY, Pfizer-BioNTech COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, Bivalent. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure.

Cardiac disorders: myocarditis, pericarditis

Gastrointestinal disorders: diarrhea, vomiting

Immune system disorders: severe allergic reactions, including anaphylaxis, and other hypersensitivity reactions (e.g., rash, pruritus, urticaria, angioedema)

Musculoskeletal and connective tissue disorders: pain in extremity (arm)

Nervous system disorders: syncope, dizziness, febrile seizures (in children 5 through 11 years of age)

## Cardiovascular Outcomes in Patients Diagnosed With mRNA COVID-19 Vaccine-associated Myocarditis

In a longitudinal retrospective observational cohort study across 38 hospitals in the U.S., information on cardiovascular outcomes was collected on 333 patients 5 through 29 years of age who had been diagnosed with COVID-19 vaccine-associated myocarditis. Among these patients, 322 were confirmed to have received an mRNA COVID-19 vaccine encoding the S glycoprotein of the Original SARS-CoV-2. Of 331 patients, 278 had onset of symptoms following the second dose of a primary series, 33 following the first dose of a primary series, and 20 following a first booster dose<sup>1</sup>.

Among 307 patients who had been diagnosed with COVID-19 vaccine-associated myocarditis for whom follow-up information was available, 89 reported cardiac symptoms at a median follow-up of 91 days (interquartile range 25-186 days) postvaccination<sup>1</sup>.

Initial gadolinium-enhanced cardiac magnetic resonance imaging (CMR) was performed on 216 patients, of whom 177 had late gadolinium enhancement (LGE), a marker of myocardial injury. Among 161 patients who had LGE on initial CMR and who had a follow-up gadolinium-enhanced CMR at a median follow-up of 159 days (interquartile range 78-253 days), 98 had persistence of LGE. Overall, the severity of LGE decreased during follow-up. The clinical and prognostic significance of these CMR findings is not known<sup>1</sup>.

Limitations of this study include potential selection bias towards patients with more severe myocarditis who are more likely to be hospitalized and have CMR, variability in diagnostic testing, and variability in follow-up<sup>1</sup>.

## **8 USE IN SPECIFIC POPULATIONS**

### **8.1 Pregnancy**

#### Risk Summary

All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects, miscarriage and pre-eclampsia in clinically recognized pregnancies is 2% to 4%, 15% to 20%, and 5% to 7%, respectively. There are no available data with COMIRNATY use in pregnant women before 24 weeks gestation to inform about risks for major birth defects and miscarriage.

A developmental toxicity study has been performed in female rats administered the equivalent of a single human dose of COMIRNATY [encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original)] on 4 occasions, twice prior to mating and twice during gestation. These studies revealed no evidence of harm to the fetus due to the vaccine (*see Data*).

#### Clinical Considerations

##### *Disease-Associated Maternal and/or Embryo/Fetal Risk*

Pregnant individuals infected with SARS-CoV-2 are at increased risk of severe COVID-19 compared with non-pregnant individuals.

#### Data

##### *Human Data*

In Study 9, a randomized, placebo-controlled trial (NCT04754594), COVID-19 vaccine naïve, pregnant women 18 years of age and older received 2 doses of COMIRNATY (Original Monovalent) (n=173 received at least 1 dose) or placebo (n=173 received at least 1 dose), approximately 21 days apart, with the first dose administered at 24 to 34 weeks gestation (i.e., late second trimester and early third trimester of pregnancy). The trial was conducted in Brazil, South Africa, Spain, United Kingdom, and the US. The trial failed to reach target accrual (originally designed to be 4,000 participants), as it was terminated prematurely, resulting in uncertainty regarding differences in outcomes.

In an analysis which excluded participants with HIV infection, a numerical imbalance in pre-eclampsia in COMIRNATY recipients (6 of 161, 3.7%) compared with placebo recipients (2 of 163, 1.2%) was observed in this study. These data are insufficient to establish or exclude a causal relationship between COMIRNATY and pre-eclampsia.

Major or minor congenital anomalies or chromosomal abnormalities were reported in 10 of 156 (6.4%) infants born to women in the COMIRNATY group and 7 of 159 (4.4%) infants born to women in the placebo group (see Table 13). Some infants had more than one event listed in the table. The available trial data are insufficient to establish or exclude vaccine-associated risk of congenital anomalies because COMIRNATY was not administered in the first trimester (the period when the risk of major congenital anomalies is highest). In addition, predisposing factors including genetic risk factors and potential maternal risk factors were reported in some cases in the COMIRNATY group.

Descriptive immunogenicity analyses of geometric mean [neutralizing] titers (GMT) in pregnant participants compared with GMTs from non-pregnant participants enrolled in another study (Study 2) were inconclusive due to study limitations including a small sample size.

**Table 13: Study 9 – Number and Percentage of Infants With Major and Minor Congenital Anomalies and Chromosomal Abnormalities Following Maternal Exposure to COMIRNATY or Placebo at or After 24 Weeks of Gestation**

<b>Congenital Anomalies and Chromosomal Abnormalities</b>	<b>COMIRNATY N<sup>a</sup>=156 n<sup>b</sup> (%)</b>	<b>Placebo N<sup>a</sup>=159 n<sup>b</sup> (%)</b>
Major Congenital Anomalies <sup>c</sup>	6 (3.8)	2 (1.3)
Atrial septal defects	4 (2.6) <sup>d</sup>	1 (0.6)
Microcephaly	2 (1.3) <sup>e</sup>	0
Central nervous system anomalies	1 (0.6) <sup>f</sup>	0
Patent ductus arteriosus	1 (0.6) <sup>g</sup>	1 (0.6)
Ventricular septal defect	0	1 (0.6)
Vesicoureteral reflux	1 (0.6) <sup>h</sup>	0
Chromosomal Abnormalities <sup>i</sup>	3 (1.9)	0
DiGeorge’s syndrome	1 (0.6) <sup>h</sup>	0
Mucopolysaccharidosis	1 (0.6) <sup>j</sup>	0
Trisomy 21	1 (0.6) <sup>d,e,g,k</sup>	0
Minor Congenital Anomalies <sup>c</sup>	3 (1.9)	5 (3.1)
Ankyloglossia congenital	1 (0.6)	4 (2.5)
Congenital skin dimples	0	2 (1.3)
Phimosis	0	1 (0.6)

Polydactyly	1 (0.6)	0
Syndactyly	1 (0.6)	0
Other	1 (0.6)	0
Congenital rubella syndrome	1 (0.6) <sup>j</sup>	0

- a. N = number of infants born to women who received at least 1 dose of the study intervention; infants born to maternal participants living with HIV were excluded from this analysis.
- b. n = number of infants with event, some infants had more than 1 event.
- c. These anomalies occur in the development of a fetus prior to Week 24 of gestation.
- d. Among infants born to women in the COMIRNATY group, atrial septal defect (ASD) occurred in 1 infant with Trisomy 21, 1 infant with central nervous system anomalies (see footnote f), 1 infant with a maternal history of congenital heart disease, and 1 infant with significant risks for ASD (maternal alcohol and tobacco use during pregnancy).
- e. Among infants born to women in the COMIRNATY group, microcephaly occurred in 1 infant with Trisomy 21 and 1 infant with significant risks for microcephaly (gestational hypertension, thyroid disease, and alcohol use during pregnancy).
- f. In 1 infant born to a woman in the COMIRNATY group, the following central nervous system anomalies were observed: lissencephaly and bilateral chorioretinitis.
- g. Among infants born to women in the COMIRNATY group, patent ductus arteriosus (PDA) occurred in 1 infant who also had Trisomy 21.
- h. Among infants born to women in the COMIRNATY group, vesicoureteral reflux occurred in the infant who also had DiGeorge's syndrome (with family history of DiGeorge's syndrome).
- i. These abnormalities occur at the time of conception.
- j. In 1 infant born to a woman in the COMIRNATY group, mucopolysaccharidosis and congenital rubella syndrome were reported.
- k. In 1 infant born to a woman in the COMIRNATY group with Trisomy 21 who presented with ASD, PDA and microcephaly, only Trisomy 21 was reported as an adverse event and the remaining manifestations were not reported as separate adverse events by the investigator.

### *Animal Data*

In a developmental toxicity study, 0.06 mL of a vaccine formulation containing the same quantity of nucleoside-modified messenger ribonucleic acid (mRNA) (30 mcg of modRNA) and other ingredients included in a single human dose of COMIRNATY [encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original)] was administered to female rats by the intramuscular route on 4 occasions: 21 and 14 days prior to mating, and on gestation days 9 and 20. No vaccine-related adverse effects on female fertility, fetal development, or postnatal development were reported in the study.

## **8.2 Lactation**

### Risk Summary

It is not known whether COMIRNATY is excreted in human milk. Data are not available to assess the effects of COMIRNATY on the breastfed infant or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for COMIRNATY and any potential adverse effects on the breastfed child from COMIRNATY or from the underlying maternal condition. For preventive vaccines, the underlying maternal condition is susceptibility to disease prevented by the vaccine.

## **8.4 Pediatric Use**

Safety and effectiveness of COMIRNATY in individuals 5 years through 17 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19 is based on safety and effectiveness data in this age group and in adults [see *Adverse Reactions (6) and Clinical Studies (14)*].

The safety and effectiveness of COMIRNATY in individuals younger than 5 years of age have not been established. Evidence from clinical studies in individuals 6 months through 4 years of age strongly suggests that a single dose of COMIRNATY would be ineffective in individuals younger than 6 months of age.

## 8.5 Geriatric Use

Of the total number of COMIRNATY recipients in Study 2 as of March 13, 2021 (N = 22,026), 20.7% (n = 4,552) were 65 years of age and older and 4.2% (n = 925) were 75 years of age and older [see *Clinical Studies (14.1)*]. In Study 4, of 5,081 recipients who received COMIRNATY as the first booster dose, 23.1% (n = 1,175) were 65 years of age and older and 5.2% (n = 265) were 75 years of age and older. In Study 5, of 726 recipients who received Pfizer-BioNTech COVID-19 Vaccine, Bivalent as the second booster dose, 21.9% (n = 159) were 65 years of age and older and 4.8% (n = 35) were 75 years of age and older [see *Clinical Studies (14.1)*]. No overall differences in safety or effectiveness were observed between these recipients and younger recipients.

## 8.6 Immunocompromised Individuals

In an open-label descriptive study (NCT04895982, Study 10), 87 immunocompromised participants 5 years of age and older received up to 4 age-appropriate doses of COMIRNATY (Original Monovalent) in a 4-dose regimen (an unapproved dosing regimen), with the first 2 doses separated by approximately 21 days, a third dose approximately 28 days after Dose 2, and a fourth dose administered approximately 3 to 6 months after Dose 3. The study evaluated safety and immunogenicity in participants 5 years through 11 years of age (n=65), 12 years through 17 years (n=15), and 18 years of age and older (n=7) with the following immunocompromising conditions: autoimmune inflammatory disorders on immunomodulatory therapy (n=31), solid organ transplant (n=25), stem cell transplant (n=29), non-small cell lung cancer (n=1), or hemodialysis (n=1). Study completion rates were 83.1% (54/65), 53.3% (8/15), and 57.1% (4/7) for the respective age groups. The trial was stopped early due to challenges with study enrollment.

Overall, 58.6% were male, 82.8% were White, 20.7% were Hispanic/Latino, 6.9% were Black or African American, 2.3% were Asian, 1.1% were American Indian or Alaska Native, 2.3% were Multiracial, and race and ethnicity was not reported by 4.6% of participants. The median age of participants in age groups 5 years through 11 years, 12 through 17 years, and 18 years of age and older was 9.0, 12.0, and 40.0 years, respectively.

The safety profile in immunocompromised participants 5 years of age and older who received COMIRNATY (Original Monovalent) was similar to that in immunocompetent participants in other clinical studies [see *Adverse Reactions (6.1)*]. There were no deaths in the study and no serious adverse events were assessed as related to vaccination.

Seroresponse rates (defined as achieving a  $\geq 4$ -fold rise in neutralizing titers from baseline) were evaluated in all participants with at least one valid immunogenicity result after vaccination, regardless of prior SARS-CoV-2 infection status.

*Among participants 5 years through 11 years of age:* At 1 month after Dose 3, seroresponse rate was 81.7% [95% confidence interval (CI): 69.6%, 90.5%] (n=60). At 1 month after Dose 4, seroresponse rate was 96.0% (95% CI: 86.3%, 99.5%) (n=50). At 6 months after Dose 4, seroresponse rate was 87.8% (95% CI: 75.2%, 95.4%) (n=49).

*Among participants 12 years through 17 years of age:* At 1 month after Dose 3, seroresponse rate was 92.9% (95% CI: 66.1%, 99.8%) (n=14). At 1 month after Dose 4, seroresponse rate was 100.0% (95% CI: 66.4%, 100.0%) (n=9). At 6 months after Dose 4, seroresponse rate was 100.0% (95% CI: 63.1%, 100.0%) (n=8).

*Among participants 18 years of age and older:* At 1 month after Dose 3, seroresponse rate was 50.0% (95% CI: 11.8%, 88.2%) (n=6). At 1 month after Dose 4, seroresponse rate was 75.0% (95% CI: 19.4%, 99.4%) (n=4). At 6 months after Dose 4, seroresponse rate was 33.3% (95% CI: 0.8%, 90.6%) (n=3).

The limitations of the study data include small sample sizes, particularly in the 12 through 17 years and  $\geq 18$  years age groups, and early study termination due to enrollment challenges. The data from this study do not establish the effectiveness of COMIRNATY in immunocompromised individuals.

The Centers for Disease Control and Prevention has published considerations related to COVID-19 vaccination guidance for people who are immunocompromised.

## 11 DESCRIPTION

COMIRNATY (COVID-19 Vaccine, mRNA) is a sterile injectable suspension for intramuscular use.

Single-Dose Prefilled Syringe for Individuals 65 Years of Age and Older and Individuals 12 Years Through 64 Years of Age with at Least One Underlying Condition that Puts Them at High Risk for Severe Outcomes from COVID-19:

Each 0.3 mL dose of COMIRNATY (2025-2026 Formula) is formulated to contain 30 mcg of a nucleoside-modified messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2 Omicron variant sublineage LP.8.1.

Each 0.3 mL dose of COMIRNATY also includes the following ingredients:  
lipids (0.43 mg ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate),  
0.05 mg 2-(polyethylene glycol 2000)-N,N-ditetradecylacetamide,  
0.09 mg 1,2-distearoyl-sn-glycero-3-phosphocholine, and 0.19 mg cholesterol), 0.06 mg tromethamine,  
0.4 mg tromethamine hydrochloride, and 31 mg sucrose.

Single-Dose Vial for Individuals 5 Years Through 11 Years of Age with at Least One Underlying Condition that Puts Them at High Risk for Severe Outcomes from COVID-19:

Each 0.3 mL dose of COMIRNATY (2025-2026 Formula) is formulated to contain 10 mcg of a modRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2 Omicron variant sublineage LP.8.1.

Each 0.3 mL dose of COMIRNATY also includes the following ingredients:  
lipids (0.14 mg ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate),  
0.02 mg 2-(polyethylene glycol 2000)-N,N-ditetradecylacetamide,  
0.03 mg 1,2-distearoyl-sn-glycero-3-phosphocholine, and 0.06 mg cholesterol), 0.06 mg tromethamine, 0.4 mg tromethamine hydrochloride, and 31 mg sucrose.

COMIRNATY does not contain preservatives.

The vial stoppers are not made with natural rubber latex.

The prefilled syringe tip cap and plunger stopper are not made with natural rubber latex.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

The nucleoside-modified mRNA in COMIRNATY is formulated in lipid particles, which enable delivery of the mRNA into host cells to allow expression of the SARS-CoV-2 S antigen. The vaccine elicits an immune response to the S antigen, which protects against COVID-19.

## 13 NONCLINICAL TOXICOLOGY

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

COMIRNATY has not been evaluated for the potential to cause carcinogenicity, genotoxicity, or impairment of male fertility. In a developmental toxicity study in rats with COMIRNATY [encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original)] there were no vaccine-related effects on female fertility [see *Use in Specific Populations (8.1)*].

## 14 CLINICAL STUDIES

### 14.1 Adults and Adolescents 12 Years of Age and Older

#### Efficacy of Two-Dose Series (Original Monovalent) in Vaccine-Naïve Individuals 16 Years of Age and Older

Study 2 is an ongoing, multicenter, multinational, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate–selection, and efficacy study in participants 12 years of age and older. Randomization was stratified by age: 12 through 15 years of age, 16 through 55 years of age, or 56 years of age and older, with a minimum of 40% of participants in the  $\geq 56$ -year stratum. The study excluded participants who were immunocompromised and those who had previous clinical or microbiological diagnosis of COVID-19. Participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, were included as were participants with known stable infection with HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV).

In Study 2, based on data accrued through March 13, 2021, approximately 44,000 participants 12 years of age and older were randomized equally and received 2 doses of COMIRNATY or placebo. Participants are planned to be followed for up to 24 months, for assessments of safety and efficacy against COVID-19.

Overall, among the total participants who received COMIRNATY or placebo, 51.4% and 50.3% were male and 48.6% and 49.7% were female, 79.1% and 79.2% were 16 through 64 years of age, 20.9% and 20.8% were 65 years of age and older, 81.9% and 82.1% were White, 9.5% and 9.6% were Black or African American, 1.0% and 0.9% were American Indian or Alaska Native, 4.4% and 4.3% were Asian, 0.3% and 0.2% Native Hawaiian or other Pacific Islander, 25.6% and 25.4% were Hispanic/Latino, 73.9% and 74.1% were non-Hispanic/Latino, 0.5% and 0.5% did not report ethnicity, 46.0% and 45.7% had comorbidities [participants who have 1 or more comorbidities that increase the risk of severe COVID-19 disease: defined as subjects who had at least 1 of the Charlson comorbidity index category or body mass index (BMI)  $\geq 30$  kg/m<sup>2</sup>], respectively. The mean age at vaccination was 49.8 and 49.7 years and median age was 51.0 and 51.0 in participants who received COMIRNATY or placebo, respectively.

## Efficacy Against COVID-19

The population for the analysis of the protocol pre-specified primary efficacy endpoint included 36,621 participants 12 years of age and older (18,242 in the COMIRNATY group and 18,379 in the placebo group) who did not have evidence of prior infection with SARS-CoV-2 through 7 days after the second dose. The population in the protocol pre-specified primary efficacy analysis included all participants 12 years of age and older who had been enrolled from July 27, 2020, and followed for the development of COVID-19 through November 14, 2020. Participants 18 through 55 years of age and 56 years of age and older began enrollment from July 27, 2020, 16 through 17 years of age began enrollment from September 16, 2020, and 12 through 15 years of age began enrollment from October 15, 2020.

For participants without evidence of SARS-CoV-2 infection prior to 7 days after Dose 2, vaccine efficacy against confirmed COVID-19 occurring at least 7 days after Dose 2 was 95.0% (95% credible interval: 90.3, 97.6), which met the pre-specified success criterion. The case split was 8 COVID-19 cases in the COMIRNATY group compared to 162 COVID-19 cases in the placebo group.

The population for the updated vaccine efficacy analysis included participants 16 years of age and older who had been enrolled from July 27, 2020, and followed for the development of COVID-19 during blinded placebo-controlled follow-up through March 13, 2021, representing up to 6 months of follow-up after Dose 2. There were 12,796 (60.8%) participants in the COMIRNATY group and 12,449 (58.7%) in the placebo group followed for  $\geq 4$  months after Dose 2 in the blinded placebo-controlled follow-up period.

SARS-CoV-2 variants of concern identified from COVID-19 cases for this age group from this data cutoff include B.1.1.7 (Alpha) and B.1.351 (Beta). Representation of identified variants among cases in vaccine versus placebo recipients did not suggest decreased vaccine effectiveness against these variants.

The updated vaccine efficacy information is presented in Table 14.

**Table 14: Vaccine Efficacy – First COVID-19 Occurrence From 7 Days After Dose 2, by Age Subgroup – Participants 16 Years of Age and Older Without Evidence of Infection and Participants With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population During the Placebo-Controlled Follow-up Period**

<b>First COVID-19 occurrence from 7 days after Dose 2 in participants without evidence of prior SARS-CoV-2 infection*</b>			
<b>Subgroup</b>	<b>COMIRNATY<sup>†</sup> N<sup>a</sup>=19,993 Cases n<sup>1b</sup> Surveillance Time<sup>c</sup> (n<sup>2d</sup>)</b>	<b>Placebo N<sup>a</sup>=20,118 Cases n<sup>1b</sup> Surveillance Time<sup>c</sup> (n<sup>2d</sup>)</b>	<b>Vaccine Efficacy % (95% CI<sup>e</sup>)</b>
All participants	77 6.092 (19,711)	833 5.857 (19,741)	91.1 (88.8, 93.1)
16 through 64 years	70 4.859 (15,519)	709 4.654 (15,515)	90.5 (87.9, 92.7)
65 years and older	7 1.233 (4192)	124 1.202 (4226)	94.5 (88.3, 97.8)

<b>First COVID-19 occurrence from 7 days after Dose 2 in participants with or without* evidence of prior SARS-CoV-2 infection</b>			
<b>Subgroup</b>	<b>COMIRNATY<sup>†</sup> N<sup>a</sup>=21,047 Cases n1<sup>b</sup> Surveillance Time<sup>c</sup> (n2<sup>d</sup>)</b>	<b>Placebo N<sup>a</sup>=21,210 Cases n1<sup>b</sup> Surveillance Time<sup>c</sup> (n2<sup>d</sup>)</b>	<b>Vaccine Efficacy % (95% CI<sup>e</sup>)</b>
All participants	81 6.340 (20,533)	854 6.110 (20,595)	90.9 (88.5, 92.8)
16 through 64 years	74 5.073 (16,218)	726 4.879 (16,269)	90.2 (87.5, 92.4)
65 years and older	7 1.267 (4315)	128 1.232 (4326)	94.7 (88.7, 97.9)

Abbreviations: CI = confidence interval; NAAT = nucleic acid amplification test; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: Confirmed cases were determined by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and at least 1 symptom consistent with COVID-19 (symptoms included: fever; new or increased cough; new or increased shortness of breath; chills; new or increased muscle pain; new loss of taste or smell; sore throat; diarrhea; vomiting).

\* Participants who had no evidence of past SARS-CoV-2 infection (i.e., N-binding antibody [serum] negative at Visit 1 and SARS-CoV-2 not detected by NAAT [nasal swab] at Visits 1 and 2) and had negative NAAT (nasal swab) at any unscheduled visit prior to 7 days after Dose 2 were included in the analysis.

† Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants in the specified group.

b. n1 = Number of participants meeting the endpoint definition.

c. Total surveillance time in 1,000 person-years for the given endpoint across all participants within each group at risk for the endpoint. Time period for COVID-19 case accrual is from 7 days after Dose 2 to the end of the surveillance period.

d. n2 = Number of participants at risk for the endpoint.

e. Two-sided confidence interval (CI) for vaccine efficacy is derived based on the Clopper and Pearson method adjusted to the surveillance time.

Subgroup analyses of vaccine efficacy (although limited by small numbers of cases in some subgroups) did not suggest meaningful differences in efficacy across sex, ethnic groups, geographies, or for participants with obesity or medical comorbidities associated with high risk of severe COVID-19.

### Efficacy Against Severe COVID-19

Efficacy analyses of secondary efficacy endpoints supported the benefit of COMIRNATY in preventing severe COVID-19. Vaccine efficacy against severe COVID-19 is presented only for participants with or without prior SARS-CoV-2 infection (Table 15) as the COVID-19 case counts in participants without prior SARS-CoV-2 infection were the same as those in participants with or without prior SARS-CoV-2 infection in both the COMIRNATY and placebo groups.

**Table 15: Vaccine Efficacy – First Severe COVID-19 Occurrence in Participants 16 Years of Age and Older With or Without\* Prior SARS-CoV-2 Infection Based on Protocol† or Centers for Disease Control and Prevention (CDC)‡ Definition From 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population During the Placebo-Controlled Follow-up**

<b>Vaccine Efficacy – First Severe COVID-19 Occurrence</b>			
	<b>COMIRNATY§ Cases n1<sup>a</sup> Surveillance Time<sup>b</sup> (n2<sup>c</sup>)</b>	<b>Placebo Cases n1<sup>a</sup> Surveillance Time<sup>b</sup> (n2<sup>c</sup>)</b>	<b>Vaccine Efficacy % (95% CI<sup>d</sup>)</b>
7 days after Dose 2 <sup>d</sup>	1 6.353 (20,540)	21 6.237 (20,629)	95.3 (70.9, 99.9)
<b>Vaccine Efficacy – First Severe COVID-19 Occurrence Based on CDC Definition</b>			
	<b>COMIRNATY§ Cases n1<sup>a</sup> Surveillance Time<sup>b</sup> (n2<sup>c</sup>)</b>	<b>Placebo Cases n1<sup>a</sup> Surveillance Time<sup>b</sup> (n2<sup>c</sup>)</b>	<b>Vaccine Efficacy % (95% CI<sup>d</sup>)</b>
7 days after Dose 2 <sup>d</sup>	0 6.345 (20,513)	31 6.225 (20,593)	100 (87.6, 100.0)

Abbreviations: CI = confidence interval; NAAT = nucleic acid amplification test; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: Confirmed cases were determined by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and at least 1 symptom consistent with COVID-19 (symptoms included: fever; new or increased cough; new or increased shortness of breath; chills; new or increased muscle pain; new loss of taste or smell; sore throat; diarrhea; vomiting).

\* Participants who had no evidence of past SARS-CoV-2 infection (i.e., N-binding antibody [serum] negative at Visit 1 and SARS-CoV-2 not detected by NAAT [nasal swab] at Visits 1 and 2) and had negative NAAT (nasal swab) at any unscheduled visit prior to 7 days after Dose 2 were included in the analysis.

† Severe illness from COVID-19 is defined in the protocol as confirmed COVID-19 and presence of at least 1 of the following:

- Clinical signs at rest indicative of severe systemic illness (respiratory rate  $\geq 30$  breaths per minute, heart rate  $\geq 125$  beats per minute, saturation of oxygen  $\leq 93\%$  on room air at sea level, or ratio of arterial oxygen partial pressure to fractional inspired oxygen  $< 300$  mm Hg);
- Respiratory failure [defined as needing high flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)];
- Evidence of shock (systolic blood pressure  $< 90$  mm Hg, diastolic blood pressure  $< 60$  mm Hg, or requiring vasopressors);
- Significant acute renal, hepatic, or neurologic dysfunction;
- Admission to an Intensive Care Unit;
- Death.

‡ Severe illness from COVID-19 as defined by CDC is confirmed COVID-19 and presence of at least 1 of the following:

- Hospitalization;
- Admission to the Intensive Care Unit;
- Intubation or mechanical ventilation;
- Death.

§ Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. n1 = Number of participants meeting the endpoint definition.

b. Total surveillance time in 1,000 person-years for the given endpoint across all participants within each group at risk for the endpoint. Time period for COVID-19 case accrual is from 7 days after Dose 2 to the end of the surveillance period.

c. n2 = Number of participants at risk for the endpoint.

d. Two-side confidence interval (CI) for vaccine efficacy is derived based on the Clopper and Pearson method adjusted to the surveillance time.

## Efficacy and Immunogenicity of Two-Dose Series (Original Monovalent) in Vaccine-Naïve Adolescents 12 Through 15 Years of Age

A descriptive efficacy analysis of Study 2 has been performed in 2,260 adolescents 12 through 15 years of age evaluating confirmed COVID-19 cases accrued up to a data cutoff date of September 2, 2021.

The vaccine efficacy information in adolescents 12 through 15 years of age is presented in Table 16.

**Table 16: Vaccine Efficacy – First COVID-19 Occurrence From 7 Days After Dose 2: Without Evidence of Infection and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period, Adolescents 12 Through 15 Years of Age Evaluable Efficacy (7 Days) Population**

<b>First COVID-19 occurrence from 7 days after Dose 2 in adolescents 12 through 15 years of age without evidence of prior SARS-CoV-2 infection*</b>			
	<b>COMIRNATY<sup>†</sup></b> <b>N<sup>a</sup>=1057</b> <b>Cases</b> <b>n<sup>1b</sup></b> <b>Surveillance Time<sup>c</sup> (n<sup>2d</sup>)</b>	<b>Placebo</b> <b>N<sup>a</sup>=1030</b> <b>Cases</b> <b>n<sup>1b</sup></b> <b>Surveillance Time<sup>c</sup> (n<sup>2d</sup>)</b>	<b>Vaccine Efficacy %</b> <b>(95% CI<sup>e</sup>)</b>
Adolescents 12 through 15 years of age	0 0.343 (1043)	28 0.322 (1019)	100.0 (86.8, 100.0)
<b>First COVID-19 occurrence from 7 days after Dose 2 in adolescents 12 through 15 years of age with or without evidence of prior SARS-CoV-2 infection</b>			
	<b>COMIRNATY<sup>†</sup></b> <b>N<sup>a</sup>=1119</b> <b>Cases</b> <b>n<sup>1b</sup></b> <b>Surveillance Time<sup>c</sup> (n<sup>2d</sup>)</b>	<b>Placebo</b> <b>N<sup>a</sup>=1109</b> <b>Cases</b> <b>n<sup>1b</sup></b> <b>Surveillance Time<sup>c</sup> (n<sup>2d</sup>)</b>	<b>Vaccine Efficacy %</b> <b>(95% CI<sup>e</sup>)</b>
Adolescents 12 through 15 years of age	0 0.362 (1098)	30 <sup>f</sup> 0.345 (1088)	100.0 (87.5, 100.0)

Abbreviations: CI = confidence interval; NAAT = nucleic acid amplification test; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: Confirmed cases were determined by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and at least 1 symptom consistent with COVID-19 (symptoms included: fever; new or increased cough; new or increased shortness of breath; chills; new or increased muscle pain; new loss of taste or smell; sore throat; diarrhea; vomiting).

\* Participants who had no evidence of past SARS-CoV-2 infection (i.e., N-binding antibody [serum] negative at Visit 1 and SARS-CoV-2 not detected by NAAT [nasal swab] at Visits 1 and 2) and had negative NAAT (nasal swab) at any unscheduled visit prior to 7 days after Dose 2 were included in the analysis.

<sup>†</sup> Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants in the specified group.

b. n1 = Number of participants meeting the endpoint definition.

c. Total surveillance time in 1,000 person-years for the given endpoint across all participants within each group at risk for the endpoint. Time period for COVID-19 case accrual is from 7 days after Dose 2 to the end of the surveillance period.

d. n2 = Number of participants at risk for the endpoint.

e. Two-side confidence interval (CI) for vaccine efficacy is derived based on the Clopper and Pearson method adjusted for surveillance time.

f. The only SARS-CoV-2 variant of concern identified from COVID-19 cases in this age group from this data cutoff was B.1.1.7 (Alpha).

In Study 2, an analysis of SARS-CoV-2 50% neutralizing titers (NT50) 1 month after Dose 2 in a randomly selected subset of participants demonstrated noninferior immune responses (within 1.5-fold) comparing

adolescents 12 through 15 years of age to participants 16 through 25 years of age who had no serological or virological evidence of past SARS-CoV-2 infection up to 1 month after Dose 2 (Table 17).

**Table 17: Summary of Geometric Mean Ratio for 50% Neutralizing Titer – Comparison of Adolescents 12 Through 15 Years of Age to Participants 16 Through 25 Years of Age (Immunogenicity Subset) – Participants Without Evidence of Infection up to 1 Month After Dose 2 – Dose 2 Evaluable Immunogenicity Population**

		COMIRNATY*		12 Through 15 Years/ 16 Through 25 Years	
		12 Through 15 Years n <sup>a</sup> =190	16 Through 25 Years n <sup>a</sup> =170		
Assay	Time Point <sup>b</sup>	GMT <sup>c</sup> (95% CI <sup>c</sup> )	GMT <sup>c</sup> (95% CI <sup>c</sup> )	GMR <sup>d</sup> (95% CI <sup>d</sup> )	Met Noninferiority Objective <sup>e</sup> (Y/N)
SARS-CoV-2 neutralization assay - NT50 (titer) <sup>f</sup>	1 month after Dose 2	1253.6 (1117.7, 1406.1)	708.1 (625.9, 801.1)	1.77 (1.50, 2.09)	Y

Abbreviations: CI = confidence interval; GMR = geometric mean ratio; GMT = geometric mean titer; LLOQ = lower limit of quantitation; NAAT = nucleic acid amplification test; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: Participants who had no serological or virological evidence (up to 1 month after receipt of the last dose) of past SARS-CoV-2 infection (i.e., N-binding antibody [serum] negative at Visit 1 and SARS-CoV-2 not detected by NAAT [nasal swab] at Visits 1 and 2), and had negative NAAT (nasal swab) at any unscheduled visit up to 1 month after Dose 2 were included in the analysis.

\* Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

- n = Number of participants with valid and determinate assay results for the specified assay at the given dose/sampling time point.
- Protocol-specified timing for blood sample collection.
- GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to  $0.5 \times \text{LLOQ}$ .
- GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (Group 1 [12 through 15 years of age] – Group 2 [16 through 25 years of age]) and the corresponding CI (based on the Student t distribution).
- Noninferiority is declared if the lower bound of the 2-sided 95% CI for the GMR is greater than 0.67.
- SARS-CoV-2 NT50 were determined using the SARS-CoV-2 mNeonGreen Virus Microneutralization Assay. The assay uses a fluorescent reporter virus derived from the USA\_WA1/2020 strain and virus neutralization is read on Vero cell monolayers. The sample NT50 is defined as the reciprocal serum dilution at which 50% of the virus is neutralized.

### Immunogenicity of Single Dose (Original Monovalent) in Vaccine-Experienced Adults 18 Years Through 55 Years of Age

Effectiveness of a booster dose of COMIRNATY was based on an assessment of 50% neutralizing antibody titers (NT50) against SARS-CoV-2 reference strain (USA\_WA1/2020) in Study 2 participants 18 through 55 years of age (n = 200 – 212) who had no serological or virological evidence of past SARS-CoV-2 infection up to 1 month after the booster vaccination. Analyses of NT50 1 month after the booster dose compared with 1 month after the primary series demonstrated noninferiority for both geometric mean ratio (GMR) [3.26 (97.5% CI: 2.76, 3.86)] and difference in seroresponse rates (percentage) [4.5% (97.5% CI: 1.0, 7.9)]. Seroresponse for a participant was defined as achieving a  $\geq 4$ -fold rise in NT50 from baseline (before primary series).

Immunogenicity of a Single Dose (Bivalent Original and BA.4/BA.5) in Vaccine-Experienced Individuals 12 Years of Age and Older

In an analysis of a subset from Study 5, 105 participants 12 through 17 years of age, 297 participants 18 through 55 years of age, and 286 participants 56 years of age and older who had previously received a 2-dose primary series and 1 booster dose with COMIRNATY received a second booster dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent. In participants 12 through 17 years of age, 18 through 55 years of age, and 56 years of age and older, 75.2%, 71.7% and 61.5% were positive for SARS-CoV-2 at baseline, respectively.

Analyses of NT50 against Omicron BA.4/BA.5 and against reference strain among participants 56 years of age and older who received a second booster dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent in Study 5 compared with a subset of participants from Study 4 who received a second booster dose of COMIRNATY demonstrated superiority of Pfizer-BioNTech COVID-19 Vaccine, Bivalent to COMIRNATY based on GMR and noninferiority based on difference in seroresponse rates with respect to anti-Omicron BA.4/BA.5 response, and noninferiority of anti-reference strain immune response based on GMR (Table 18 and Table 19).

Analyses of NT50 against Omicron BA.4/BA.5 among participants 18 through 55 years of age compared with participants 56 years of age and older who received a second booster dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent in Study 5 demonstrated noninferiority of anti-Omicron BA.4/BA.5 response among participants 18 through 55 years of age to participants 56 years of age and older for both GMR and difference in seroresponse rates (Table 18 and Table 19).

The study also assessed the level of NT50 against the anti-Omicron BA.4/BA.5 and original SARS-CoV-2 strains pre-vaccination and 1 month after vaccination in participants who received a second booster dose (Table 20).

**Table 18: Geometric Mean Titer Ratios – Study 5 COMIRNATY – Participants With or Without Evidence of Infection – Evaluable Immunogenicity Population**

SARS-CoV-2 Neutralization Assay	Sampling Time Point <sup>a</sup>	Pfizer-BioNTech COVID-19 Vaccine, Bivalent* Study 5				COMIRNATY <sup>†</sup> Subset of Study 4		Age Group Comparison	Vaccine Group Comparison
		18 Through 55 Years of Age		56 Years of Age and Older		56 Years of Age and Older		Pfizer-BioNTech COVID-19 Vaccine, Bivalent* 18 Through 55 Years of Age ≥56 Years of Age	≥56 Years of Age Pfizer-BioNTech COVID-19 Vaccine, Bivalent* / COMIRNATY <sup>†</sup>
		n <sup>b</sup>	GMT <sup>c</sup> (95% CI) <sup>c</sup>	n <sup>b</sup>	GMT <sup>c</sup> (95% CI) <sup>c</sup>	n <sup>b</sup>	GMT <sup>c</sup> (95% CI) <sup>c</sup>		
Omicron BA.4/BA.5 - NT50 (titer) <sup>e</sup>	1 Month	297	4455.9 (3851.7, 5154.8)	284	4158.1 (3554.8, 4863.8)	282	938.9 (802.3, 1098.8)	0.98 (0.83, 1.16) <sup>f</sup>	2.91 (2.45, 3.44) <sup>g</sup>
Reference Strain – NT50 (titer) <sup>e</sup>	1 Month	-	-	286	16250.1 (14499.2, 18212.4)	289	10415.5 (9366.7, 11581.8)	-	1.38 (1.22, 1.56) <sup>h</sup>

Abbreviations: GMT = geometric mean titer; LLOQ = lower limit of quantitation; N-binding = SARS-CoV-2 nucleoprotein-binding; NAAT = nucleic acid amplification test; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

\* Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original) and Omicron variant lineages BA.4 and BA.5 (Omicron BA.4/BA.5).

† Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

- Protocol-specified timing for blood sample collection.
- n = Number of participants with valid and determinate assay results for the specified assay at the given sampling time point.
- GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to  $0.5 \times \text{LLOQ}$ .
- GMRs and 2-sided 95% CIs were calculated by exponentiating the difference of LS means and corresponding CIs based on analysis of logarithmically transformed neutralizing titers using a linear regression model with terms of baseline neutralizing titer (log scale) and vaccine group or age group.
- SARS-CoV-2 NT50 were determined using a validated 384-well assay platform (original strain [USA\_WA1/2020, isolated in January 2020] and Omicron B.1.1.529 subvariant BA.4/BA.5).
- Noninferiority is declared if the lower bound of the 2-sided 95% CI for the GMR is greater than 0.67.
- Superiority is declared if the lower bound of the 2-sided 95% CI for the GMR is greater than 1.
- Noninferiority is declared if the lower bound of the 2-sided 95% CI for the GMR is greater than 0.67 and the point estimate of the GMR is  $\geq 0.8$ .

**Table 19: Difference in Percentages of Participants With Seroreponse – Pfizer-BioNTech COVID-19 Vaccine, Bivalent from Study 5 and COMIRNATY from Subset of Study 4 – Participants With or Without Evidence of Infection – Evaluable Immunogenicity Population**

		Pfizer-BioNTech COVID-19 Vaccine, Bivalent* Study 5				COMIRNATY† Subset of Study 4		Age Group Comparison	Vaccine Group Comparison
		18 Through 55 Years of Age		56 Years of Age and Older		56 Years of Age and Older		Pfizer-BioNTech COVID-19 Vaccine, Bivalent* 18 Through 55 Years of Age $\geq 56$ Years of Age	$\geq 56$ Years of Age Pfizer-BioNTech COVID-19 Vaccine, Bivalent* / COMIRNATY†
SARS-CoV-2 Neutralization Assay	Sampling Time Point <sup>a</sup>	n <sup>b</sup>	N <sup>c</sup> (%) (95% CI <sup>d</sup> )	n <sup>b</sup>	N <sup>c</sup> (%) (95% CI <sup>d</sup> )	n <sup>b</sup>	N <sup>c</sup> (%) (95% CI <sup>d</sup> )	Difference <sup>e</sup> (95% CI <sup>f</sup> )	Difference <sup>e</sup> (95% CI <sup>f</sup> )
Omicron BA.4/BA.5 - NT50 (titer) <sup>g</sup>	1 Month	294	180 (61.2) (55.4, 66.8)	282	188 (66.7) (60.8, 72.1)	273	127 (46.5) (40.5, 52.6)	-3.03 (-9.68, 3.63) <sup>h</sup>	26.77 (19.59, 33.95) <sup>i</sup>

Abbreviations: LLOQ = lower limit of quantitation; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: Seroreponse is defined as achieving a  $\geq 4$ -fold rise from baseline. If the baseline measurement is below the LLOQ, a postvaccination assay result  $\geq 4 \times \text{LLOQ}$  is considered a seroreponse.

\* Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original) and Omicron variant lineages BA.4 and BA.5 (Omicron BA.4/BA.5).

† Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

- Protocol-specified timing for blood sample collection.
- N = Number of participants with valid and determinate assay results for the specified assay at both the pre-vaccination time point and the given sampling time point. This value is the denominator for the percentage calculation.
- n = Number of participants with seroreponse for the given assay at the given sampling time point.
- Exact 2-sided CI, based on the Clopper and Pearson method.
- Difference in proportions, expressed as a percentage.
- 2-sided CI based on the Miettinen and Nurminen method stratified by baseline neutralizing titer category ( $<$ median,  $\geq$  median) for the difference in proportions. The median of baseline neutralizing titers was calculated based on the pooled data in 2 comparator groups.
- SARS-CoV-2 NT50 were determined using a validated 384-well assay platform (Omicron B.1.1.529 subvariant BA.4/BA.5).
- Noninferiority is declared if the lower bound of the 2-sided 95% CI for the difference in percentages of participants with seroreponse is  $> -10\%$ .
- Noninferiority is declared if the lower bound of the 2-sided 95% CI for the difference in percentages of participants with seroreponse is  $> -5\%$ .

**Table 20: Geometric Mean Titers – Pfizer-BioNTech COVID-19 Vaccine, Bivalent Groups Subset of Study 5 – Prior to and 1 Month After Second Booster – Participants 12 Years of Age and Older – Evaluable Immunogenicity Population**

SARS-CoV-2 Neutralization Assay	Sampling Time Point <sup>a</sup>	Pfizer-BioNTech COVID-19 Vaccine, Bivalent*					
		12 Through 17 Years of Age		18 Through 55 Years of Age		56 Years of Age and Older	
		n <sup>b</sup>	GMT <sup>c</sup> (95% CI <sup>c</sup> )	n <sup>b</sup>	GMT <sup>c</sup> (95% CI <sup>c</sup> )	n <sup>b</sup>	GMT <sup>c</sup> (95% CI <sup>c</sup> )
Omicron BA.4/BA.5 - NT50 (titer) <sup>d</sup>	Pre-vaccination	104	1105.8 (835.1, 1464.3)	294	569.6 (471.4, 688.2)	284	458.2 (365.2, 574.8)
	1 Month	105	8212.8 (6807.3, 9908.7)	297	4455.9 (3851.7, 5154.8)	284	4158.1 (3554.8, 4863.8)
Reference strain - NT50 (titer) <sup>d</sup>	Pre-vaccination	105	6863.3 (5587.8, 8430.1)	296	4017.3 (3430.7, 4704.1)	284	3690.6 (3082.2, 4419.0)
	1 Month	105	23641.3 (20473.1, 27299.8)	296	16323.3 (14686.5, 18142.6)	286	16250.1 (14499.2, 18212.4)

Abbreviations: GMT = geometric mean titer; LLOQ = lower limit of quantitation; N-binding = SARS-CoV-2 nucleoprotein-binding; NAAT = nucleic acid amplification test; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

- \* Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original) and Omicron variant lineages BA.4 and BA.5 (Omicron BA.4/BA.5).
- a. Protocol-specified timing for blood sample collection.
- b. n = Number of participants with valid and determinate assay results for the specified assay at the given sampling time point.
- c. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to  $0.5 \times \text{LLOQ}$ .
- d. SARS-CoV-2 NT50 were determined using a validated 384-well assay platform (original strain [USA\_WA1/2020, isolated in January 2020] and Omicron B.1.1.529 subvariant BA.4/BA.5).

### Immunogenicity of a Single Dose (Bivalent Alpha and Delta) in Seropositive, Vaccine-Naïve Adults 18 Years of Age and Older

In a post-hoc analysis in a subset of participants 18 through 85 years of age enrolled in Study 7 (NCT05004181), immunogenicity of a single dose of a Pfizer-BioNTech bivalent COVID-19 vaccine containing equal quantities of modRNA (30 mcg total) encoding the viral spike (S) glycoprotein for the Alpha and Delta SARS-CoV-2 variants [not authorized or approved in the U.S., hereafter referred to as bivalent vaccine (Alpha and Delta)] was assessed in COVID-19 vaccine-naïve participants with evidence of prior SARS-CoV-2 infection (n = 262) compared with participants without prior SARS-CoV-2 infection who received 2 doses of COMIRNATY in Study 2 (n = 275). Among Study 7 participants, 253 were from study sites in South Africa and 9 were from study sites in the U.S. The immunogenicity of the bivalent Alpha and Delta vaccine is relevant to COMIRNATY because these vaccines are manufactured using the same process with differences only in the encoded spike proteins.

Table 21 presents demographic characteristics for participants in the immunogenicity analysis set.

**Table 21: Demographic Characteristics – Subset of Participants from Study 7 and Study 2 – Reference Strain Neutralization – Immunogenicity Analysis Set**

	<b>Study 7 Single Dose of Bivalent Vaccine (Alpha and Delta) With Evidence of Prior Infection (N<sup>a</sup>=262) N<sup>b</sup> (%)</b>	<b>Study 2 Two Doses of COMIRNATY* Without Evidence of Infection (N<sup>a</sup>=275) N<sup>b</sup> (%)</b>
<b>Sex</b>		
Male	109 (41.6)	113 (41.1)
Female	153 (58.4)	162 (58.9)
<b>Age at Vaccination (Years)</b>		
Mean (SD)	42.9 (16.21)	42.7 (16.08)
Median	41.0	40.0
Min, max	(18,84)	(18, 84)
<b>Race</b>		
White	4 (1.5)	230 (83.6)
Black or African American	169 (64.5)	25 (9.1)
American Indian or Alaska Native	0	2 (0.7)
Asian	0	7 (2.5)
Other <sup>c</sup>	89 (34.0)	11 (4.0)
<b>Ethnicity</b>		
Hispanic or Latino	5 (1.9)	83 (30.2)
Not Hispanic or Latino	255 (97.3)	192 (69.8)
Not reported	2 (0.8)	0

\* Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

a. N = Number of participants in the specified group. This value is the denominator for the percentage calculations.

b. n = Number of participants with the specified characteristic.

c. Includes multiracial and not reported.

The objective of this analysis was to assess noninferiority with respect to level of 50% neutralizing titer (NT50) and to the seroresponse rate to the reference strain induced by a single dose of the bivalent Alpha and Delta vaccine in COVID-19 vaccine-naïve participants with evidence of prior infection relative to participants without evidence of SARS-CoV-2 infection who received 2 doses of COMIRNATY.

Noninferiority of the reference strain immune response with respect to level of NT50 was met, as the lower bound of the 2-sided 95% CI for the geometric mean ratio (GMR) was >0.67 (Table 22). Noninferiority of the seroresponse rate to the reference strain was not met, as the lower bound of the 2-sided 95% CIs for the difference in seroresponse rate of reference strain was -10.04%, below the noninferiority margin of -10% (Table 23).

**Table 22: Geometric Mean Ratios – Single Dose of Bivalent Vaccine (Alpha and Delta) in Vaccine-Naïve Participants from Study 7 With Evidence of Prior SARS-CoV-2 Infection Compared With 2 Doses of COMIRNATY in a Subset of Participants from Study 2 Without Evidence of SARS-CoV-2 Infection – Reference Strain Neutralization – Immunogenicity Analysis Set**

	Study 7 Single Dose of Bivalent Vaccine (Alpha and Delta) With Evidence of Prior Infection <sup>a</sup> 3 Weeks After Dose 1 <sup>b</sup>		Study 2 Two Doses of COMIRNATY* Without Evidence of Infection <sup>c</sup> 1 Month After Dose 2 <sup>b</sup>		Bivalent Vaccine (Alpha and Delta) With Evidence of Prior Infection <sup>b</sup> / COMIRNATY Without Evidence of Infection <sup>c</sup>
SARS-CoV-2 Neutralization Assay	n <sup>d</sup>	GMT <sup>e</sup> (95% CI <sup>e</sup> )	n <sup>d</sup>	GMT <sup>e</sup> (95% CI <sup>e</sup> )	GMR <sup>f</sup> (95% CI <sup>f</sup> )
Reference strain - NT50 (titer) <sup>g</sup>	262	17404.2 (15485.1, 19561.1)	275	1328.1 (1183.1, 1491.0)	13.12 (11.14, 15.45) <sup>h</sup>

Abbreviations: CI = confidence interval; GMR = geometric mean ratio; GMT = geometric mean titer; LLOQ = lower limit of quantitation; N-binding = SARS-CoV-2 nucleoprotein-binding; NAAT = nucleic acid amplification test; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

\* Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

- a. Participants with positive N-binding antibody result at baseline, positive NAAT result prior to vaccination, or medical history or adverse event of COVID-19 prior to vaccination.
- b. Protocol-specified timing for blood sample collection.
- c. Participants who had no serological or virological evidence (up to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection (i.e., negative N-binding antibody [serum] result at the Dose 1 and 1-month post-Dose 2 visits, negative NAAT [nasal swab] at the Dose 1 and Dose 2 visits, and any unscheduled visit [up to the 1-month post-Dose 2 blood sample collection]) and had no medical history of COVID-19 were included in the analysis.
- d. n = Number of participants with valid and determinate assay results for the specified assay at the given sampling time point.
- e. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to  $0.5 \times \text{LLOQ}$ .
- f. GMRs and 2-sided 95% CIs were calculated by exponentiating the difference of LS means and corresponding CIs based on the analysis of logarithmically transformed neutralizing titers using a linear regression model with terms of age, sex, and group. Assay results below the LLOQ were set to  $0.5 \times \text{LLOQ}$ .
- g. SARS-CoV-2 NT50 were determined using a validated 384-well assay platform (original strain [USA\_WA1/2020, isolated in January 2020]).
- h. Noninferiority is declared if the lower bound of the 2-sided 95% CI for the GMR is greater than 0.67.

**Table 23: Difference in Percentages of Participants With Seroreponse – Bivalent Vaccine (Alpha and Delta) in Vaccine-Naïve Participants from Study 7 With Evidence of Prior SARS-CoV-2 Infection Compared With 2 Doses of COMIRNATY in a Subset of Participants from Study 2 Without Evidence of Prior SARS-CoV-2 Infection – Reference Strain Neutralization – Immunogenicity Analysis Set**

	Study 7 Bivalent Vaccine (Alpha and Delta) With Evidence of Prior Infection <sup>a</sup> 3 Weeks After Dose 1 <sup>b</sup>		Study 2 COMIRNATY* Without Evidence of Prior Infection <sup>c</sup> 1 Month After Dose 2 <sup>b</sup>		Bivalent Vaccine (Alpha and Delta) With Evidence of Prior Infection <sup>a</sup> Minus COMIRNATY Without Evidence of Prior Infection <sup>c</sup>	
SARS-CoV-2 Neutralization Assay	N <sup>d</sup>	n <sup>e</sup> (%) (95% CI) <sup>f</sup>	N <sup>d</sup>	n <sup>e</sup> (%) (95% CI) <sup>f</sup>	Difference % <sup>g</sup>	95% CI <sup>h</sup>
Reference strain – NT50 (titer) <sup>i</sup>	260	223 (85.8) (80.9, 89.8)	275	249 (90.5) (86.5, 93.7)	-4.55	(-10.04, 0.83) <sup>j</sup>

Abbreviations: CI = confidence interval; N-binding = SARS-CoV-2 nucleoprotein-binding; NAAT = nucleic acid amplification test; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

\* Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

- a. Participants with positive N-binding antibody result at baseline, positive NAAT result prior to vaccination, or medical history or adverse event of COVID-19 prior to vaccination.
- b. Protocol-specified timing for blood sample collection.
- c. Participants who had no serological or virological evidence (up to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection (i.e., negative N-binding antibody [serum] result at the Dose 1 and 1-month post-Dose 2 visits, negative NAAT [nasal swab] at the Dose 1 and Dose 2 visits, and any unscheduled visit [up to the 1-month post-Dose 2 blood sample collection]) and had no medical history of COVID-19 were included in the analysis.
- d. N = Number of participants with valid and determinate assay results for the specified assay at both the pre-vaccination time point and the given sampling time point. This value is the denominator for the percentage calculation.
- e. n = Number of participants with seroreponse for the given assay at the given sampling time point.
- f. Exact 2-sided CI, based on the Clopper and Pearson method.
- g. Adjusted difference in proportions estimated using minimum risk weights and stratified by sex and age group (18 to 55 years, 56 to 85 years), expressed as a percentage.
- h. 2-sided CI based on the Newcombe method stratified by sex and age group (18 to 55 years, 56 to 85 years) with minimum risk weights for the difference in proportions.
- i. SARS-CoV-2 NT50 were determined using a validated 384-well assay platform (original strain [USA\_WA1/2020, isolated in January 2020]).
- j. Noninferiority is declared if the lower bound of the 2-sided 95% CI for the difference in percentages of participants with seroreponse is >-10%.

### Concomitant Administration of COMIRNATY (Original Monovalent) With Influenza Vaccine in Adults 18 Years Through 64 Years of Age

In Study 8, a Phase 3 multicenter, randomized, observer-blind study, 1,134 participants 18 through 64 years of age who had received 3 doses of COMIRNATY at least 3 months prior were randomized in a 1:1 ratio to receive either COMIRNATY concomitantly administered with Influenza Vaccine (Afluria Quadrivalent) followed 1 month later by placebo (Group 1, n = 568) or influenza vaccine with placebo followed 1 month later with COMIRNATY (Group 2, n = 566).

Full-length spike (S)-binding IgG responses to COMIRNATY and influenza strain-specific hemagglutination inhibition (HAI) titers were assessed 1-month postvaccination in each group.

The non-inferiority criteria (lower bound of the 2-sided 95% CI >0.67) for the comparison of concomitant administration versus separate administration were met. The GMC ratio of full-length S-binding IgG levels of SARS-CoV-2 Wuhan-Hu-1 strain (Original) (Group 1/Group 2) was 0.83 [95% CI: 0.77, 0.89]. The GMT ratio (Group 1/Group 2) for the 4 strain-specific influenza HAI titers were H1N1 A/Victoria: 0.95 [95% CI: 0.83, 1.09]; H3N2 A/Darwin: 0.96 [95% CI: 0.85, 1.09]; B/Austria: 0.89 [95% CI: 0.77, 1.04]; B/Phuket: 1.00 [95% CI: 0.89, 1.13].

SARS-CoV-2 Wuhan-Hu-1 strain (Original) neutralizing GMTs were descriptively assessed in a subset of participants, 100 participants from Group 1 and 100 participants from Group 2.

The SARS-CoV-2 neutralization assay (NT50 titer) GMTs increased from baseline to 1 month after vaccination with COMIRNATY from 2,755.9 to 6,773.9 in Group 1 and from 2,421.2 to 7,886.6 in Group 2.

## **14.2 Children 5 Years Through 11 Years of Age**

### Efficacy and Immunogenicity of Two-Dose Series (Original Monovalent) in Vaccine-Naïve Children 5 Years Through 11 Years of Age

An efficacy analysis of Study 3 has been performed in 4,051 participants 5 years through 11 years of age without evidence of infection prior to 7 days after Dose 2. This analysis evaluated confirmed symptomatic COVID-19 cases in the placebo-controlled blinded follow-up period accrued up to a data cutoff date of 20 May 2022.

In Study 3, participants 5 years through 11 years of age were enrolled in the United States, Spain, Finland, and Poland. Among participants 5 years through 11 years of age without evidence of prior infection with SARS-CoV-2 through 7 days after Dose 2, who received COMIRNATY (n=2,703) or placebo (n=1,348) in the evaluable efficacy population, 51.2% and 51.0% were male, 48.8% and 49.0% were female, 76.3% and 77.2% were White, 5.5% and 6.0% were Black or African American, 0.5% and 0.3% were American Indian or Alaska Native, 8.9% and 8.5% were Asian, 0.3% and 0% were Native Hawaiian or other Pacific Islander, 8.5% and 7.9% were multiracial or not reported, 15.1% and 15.7% were Hispanic/Latino, 84.8% and 84.3% were non-Hispanic/Latino, and 0.1% and 0% did not report ethnicity, respectively. In the evaluable efficacy population, 25.7% and 25.9% of participants had 1 or more comorbidities that increase the risk of severe COVID-19 disease: defined as participants who had at least 1 of the pre-specified comorbidities based on MMWR 69(32);1081-1088 and/or obesity (BMI  $\geq$ 95<sup>th</sup> percentile), respectively. The median age of participants at vaccination was 8.0 years with a range of 5 through 11 years of age in both the COMIRNATY and placebo groups.

The overall vaccine efficacy results and subgroup analysis in participants 5 years through 11 years of age without evidence of prior SARS-CoV-2 infection are presented in Table 24. None of the cases met criteria for severe COVID-19 or multisystem inflammatory syndrome in children (MIS-C).

**Table 24: Overall Vaccine Efficacy and Subgroup Analysis\* – First COVID-19 Occurrence From 7 Days After Dose 2 – Study 3 Participants Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy Population**

<b>First COVID-19 Occurrence From 7 Days after Dose 2</b>	<b>COMIRNATY (N<sup>a</sup>=2703) Cases n1<sup>b</sup> Surveillance Time<sup>c</sup> (n2<sup>d</sup>)</b>	<b>Placebo (N<sup>a</sup>=1348) Cases n1<sup>b</sup> Surveillance Time<sup>c</sup> (n2<sup>d</sup>)</b>	<b>Vaccine Efficacy (%) (95% CI<sup>e</sup>)</b>
Overall	10 0.591 (2640)	42 0.292 (1309)	88.2 (76.2, 94.7)
Participants with at least one comorbidity of interest <sup>f</sup>			
Yes	2 0.150 (676)	13 0.075 (336)	92.3* (66.0, 99.2)
No	8 0.441 (1964)	29 0.217 (973)	86.4* (69.5, 94.6)

Abbreviations: BMI = body mass index; MMWR = Morbidity and Mortality Weekly Report; NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein-binding; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: Participants who had no serological or virological evidence (prior to 7 days after receipt of Dose 2) of past SARS-CoV-2 infection (i.e., N-binding antibody [serum] negative at Dose 1 visit, SARS-CoV-2 not detected by NAAT [nasal swab] at Dose 1 and Dose 2 study visits, and negative NAAT [nasal swab] result at any unscheduled visit prior to 7 days after receipt of Dose 2) and had no medical history of COVID-19 were included in the analysis.

\* Subgroup analysis was not a prespecified hypothesis, and the results may not necessarily be valid inferences about vaccine efficacy.

- N = number of participants in the specified group.
- n1 = Number of participants meeting the endpoint definition.
- Total surveillance time in 1000 person-years for the given endpoint across all participants within each group at risk for the endpoint. Time period for COVID-19 case accrual is from 7 days after Dose 2 to the end of the surveillance period.
- n2 = Number of participants at risk for the endpoint.
- Two-sided 95% confidence interval (CI) for VE is derived based on the Clopper and Pearson method adjusted for surveillance time.
- Number of participants who have 1 or more comorbidities that increase the risk of severe COVID-19 disease: defined as participants who had at least one of the prespecified comorbidities based on MMWR Morb Mortal Wkly Rep. 2020;69(32):1081-8 and/or obesity (BMI ≥95th percentile).

SARS-CoV-2 50% neutralizing antibody titers (NT50) 1 month after the two-dose series were compared between randomly selected subsets of participants 5 years through 11 years of age from Study 3 (Phase 2/3) and participants 16 years through 25 years of age from efficacy Study 2 (Phase 2/3), using a microneutralization assay against the reference strain (USA\_WA1/2020). The primary immunobridging analyses compared the geometric mean titers (using a geometric mean ratio [GMR]) and the seroresponse (defined as achieving at least 4-fold rise in SARS-CoV-2 NT50 from before Dose 1) rate percentages in the evaluable immunogenicity population of participants without evidence of prior SARS-CoV-2 infection up to 1 month after Dose 2 in each group. The pre-specified noninferiority criteria were met for both the GMR and the seroresponse difference (Table 25 and Table 26).

**Table 25: SARS-CoV-2 GMTs (NT50) at 1 Month After Primary Series – Immunobridging Subset – Participants 5 Through 11 Years of Age (Study 3) and Participants 16 Through 25 Years of Age (Study 2) – Without Evidence of SARS-CoV-2 Infection up to 1 Month After Dose 2 – Evaluable Immunogenicity Population**

		COMIRNATY*		GMT Ratio (95% CI) (5 Through 11 Years of Age / 16 Through 25 Years of Age) <sup>d,e</sup>
		5 Through 11 Years of Age n <sup>a</sup> =264	16 Through 25 Years of Age n <sup>a</sup> =253	
Assay	Time Point <sup>b</sup>	GMT <sup>c</sup> (95% CI <sup>c</sup> )	GMT <sup>c</sup> (95% CI <sup>c</sup> )	
SARS-CoV-2 neutralization assay – NT50 (titer) <sup>f</sup>	1 month after Dose 2	1197.6 (1106.1, 1296.6)	1146.5 (1045.5, 1257.2)	1.04 (0.93, 1.18)

Abbreviations: CI = confidence interval; GMR = geometric mean ratio; GMT = geometric mean titer; LLOQ = lower limit of quantitation; NAAT = nucleic acid amplification test; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: Participants who had no serological or virological evidence (up to 1 month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection (i.e., N-binding antibody [serum] negative at pre-Dose 1 and 1 month after Dose 2, SARS-CoV-2 not detected by NAAT [nasal swab] at pre-Dose 1 and pre-Dose 2, and negative NAAT (nasal swab) at any unscheduled visit up to 1 month after Dose 2 blood collection) and had no medical history of COVID-19 were included in the analysis.

\* Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

- n = Number of participants with valid and determinate assay results for the specified assay at the given dose/sampling time point.
- Protocol-specified timing for blood sample collection.
- GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
- GMT ratio and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (5 through 11 years of age minus 16 through 25 years of age) and the corresponding CI (based on the Student t distribution).
- Noninferiority is declared if the lower bound of the 2-sided 95% CI for the GMT ratio is greater than 0.67 and the point estimate of the GMR is ≥0.8.
- SARS-CoV-2 NT50 were determined using the SARS-CoV-2 mNeonGreen Virus Microneutralization Assay. The assay uses a fluorescent reporter virus derived from the USA\_WA1/2020 strain and virus neutralization is read on Vero cell monolayers. The sample NT50 is defined as the reciprocal serum dilution at which 50% of the virus is neutralized.

**Table 26: Difference in Percentages of Participants With Seroresponse at 1 Month After Primary Series – Immunobridging Subset – Participants 5 Through 11 Years of Age (Study 3) and Participants 16 Through 25 Years of Age (Study 2) Without Evidence of Infection up to 1 Month After Dose 2 – Evaluable Immunogenicity Population**

		COMIRNATY*		Difference in Seroresponse Rates % <sup>e</sup> (95% CI <sup>f</sup> ) (5 Through 11 Years of Age minus 16 Through 25 Years of Age) <sup>g</sup>
		5 Through 11 Years of Age N <sup>a</sup> =264	16 Through 25 Years of Age N <sup>a</sup> =253	
Assay	Time Point <sup>b</sup>	n <sup>c</sup> (%) (95% CI <sup>d</sup> )	n <sup>c</sup> (%) (95% CI <sup>d</sup> )	
SARS-CoV-2 neutralization assay – NT50 (titer) <sup>h</sup>	1 month after Dose 2	262 (99.2) (97.3, 99.9)	251 (99.2) (97.2, 99.9)	0.0 (-2.0, 2.2)

Abbreviations: CI = confidence interval; GMR = geometric mean ratio; LLOQ = lower limit of quantitation; NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein-binding; NT50 = 50% neutralizing titer 50; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: Seroreponse is defined as achieving a  $\geq 4$ -fold rise from baseline (before Dose 1). If the baseline measurement is below the LLOQ, a postvaccination assay result  $\geq 4 \times$  LLOQ is considered a seroreponse.

Note: Participants who had no serological or virological evidence (up to 1 month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection (i.e., N-binding antibody [serum] negative at pre-Dose 1 and 1 month after Dose 2, SARS-CoV-2 not detected by NAAT [nasal swab] at pre-Dose 1 and pre-Dose 2, and negative NAAT (nasal swab) at any unscheduled visit up to 1 month after Dose 2 blood collection) and had no medical history of COVID-19 were included in the analysis.

\* Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Wuhan-Hu-1 strain (Original).

- a. N = Number of participants with valid and determinate assay results both before vaccination and at 1 month after Dose 2. These values are the denominators for the percentage calculations.
- b. Protocol-specified timing for blood sample collection.
- c. n = Number of participants with seroreponse for the given assay at the given dose/sampling time point.
- d. Exact 2-sided CI based on the Clopper and Pearson method.
- e. Difference in proportions, expressed as a percentage (5 through 11 years of age minus 16 through 25 years of age).
- f. 2-sided CI, based on the Miettinen and Nurminen method for the difference in proportions, expressed as a percentage.
- g. Noninferiority is declared if the lower bound of the 2-sided 95% CI for the difference in proportions is greater than -10.0% provided that the immunobridging criteria based on GMR were met.
- h. SARS-CoV-2 NT50 were determined using the SARS-CoV-2 mNeonGreen Virus Microneutralization Assay. The assay uses a fluorescent reporter virus derived from the USA\_WA1/2020 strain and virus neutralization is read on Vero cell monolayers. The sample NT50 is defined as the reciprocal serum dilution at which 50% of the virus is neutralized.

### Immunogenicity of a Single Dose (Original Monovalent) in Vaccine-Experienced Children 5 Years Through 11 Years of Age

In Study 3, immunogenicity of a first booster dose of COMIRNATY administered after the second dose of the two-dose series with COMIRNATY was evaluated in 67 study participants 5 through 11 years of age who had no serological or virological evidence of past SARS-CoV-2 infection up to 1 month after the booster dose. Using a microneutralization assay against the reference strain of SARS-CoV-2 (USA\_WA1/2020), the NT50 GMT at 1 month after the booster dose (2,720.9 [95% CI: 2,280.1, 3,247.0]) was increased compared with before the booster dose (271.0 [95% CI: 229.1, 320.6]).

### Immunogenicity of a Single Dose (Monovalent XBB.1.5) in Vaccine-Naïve Children 5 Years Through 11 Years of Age

In an analysis of a subset of Study 6, immunogenicity of a single dose of COMIRNATY (encoding the viral spike (S) glycoprotein of SARS-CoV-2 Omicron XBB.1.5) in COVID-19 vaccine-naïve participants 5 through 11 years of age (n=285) was compared with participants 12 years of age and older who had received at least 3 prior U.S.-authorized mRNA COVID-19 vaccine doses and then received a single dose of COMIRNATY (encoding the viral spike (S) glycoprotein of SARS-CoV-2 Omicron XBB.1.5, 30 mcg of modRNA) in a subset of study C4591054 (Study 13; NCT 05997290) (n=302). Study 13 evaluated safety and immunogenicity of a single dose of COMIRNATY administered to COVID-19 vaccine-experienced participants 12 years of age and older. In Study 6 and Study 13, 98.9% and 99.3% of participants had evidence of prior SARS-CoV-2 infection at baseline, respectively.

Study 6 was conducted in Brazil, Puerto Rico, South Africa and United States. Among the COVID-19 vaccine-naïve participants 5 through 11 years of age in Study 6 (n=285) and COVID-19 vaccine-experienced participants 12 years of age and older in Study 13 (n=302) who received a single dose of COMIRNATY in the evaluable immunogenicity population, 46.3% and 41.7% were male, 53.7% and 58.3% were female, 41.1% and 79.1% were White, 53.0% and 12.9% were Black or African American, 0.4% and 0% were American Indian or Alaska Native, 2.1% and 5.0% were Asian, 0% and 0.3% were Native Hawaiian or other Pacific Islander, 3.5% and 2.6% were multiracial, not reported, or unknown, 53.3% and 19.2% were Hispanic/Latino, and 46.7% and 80.1% were non-Hispanic/Latino, respectively. At study vaccination, the median age of participants in Study 6

was 7.0 years (range 5 through 11 years of age) and the median age of participants in Study 13 was 53.5 years (range 12 through 82 years).

The primary immunobridging analyses compared the geometric mean titers (using a geometric mean ratio [GMR]) and the seroresponse (defined as achieving at least 4-fold rise from baseline) rates in the COVID-19 vaccine-naïve participants 5 through 11 years of age to COVID-19 vaccine-experienced participants 12 years of age and older. The noninferiority criteria were met for both the GMR and the seroresponse rate percentages (Table 27 and Table 28).

**Table 27: Geometric Mean Ratio – Study 6 to Study 13 – Participants at 1 Month After Study Vaccination – Evaluable Immunogenicity Population**

	Study 6 COVID-19 Vaccine-Naïve 5 Through 11 Years of Age COMIRNATY*		Study 13 COVID-19 Vaccine-Experienced ≥12 Years of Age COMIRNATY*		Study 6/Study 13
SARS-CoV-2 Neutralization Assay	n <sup>a</sup>	GMT <sup>b</sup> (95% CI <sup>b</sup> )	n <sup>a</sup>	GMT <sup>b</sup> (95% CI <sup>b</sup> )	GMR <sup>c</sup> (95% CI <sup>c</sup> )
Omicron XBB.1.5 - NT50 (titer) <sup>d</sup>	285	5930.5 (5283.8, 6656.4)	302	4006.4 (3438.3, 4668.4)	1.81 (1.51, 2.16) <sup>e</sup>

Abbreviations: CI = confidence interval; GMR = geometric mean ratio; GMT = geometric mean titer; LLOQ = lower limit of quantitation; LS = least square; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

\* Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Omicron XBB.1.5.

- n = Number of participants with valid and determinate assay results for the specified assay at the given sampling time point.
- GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to  $0.5 \times \text{LLOQ}$ .
- GMRs and 2-sided 95% CIs were calculated by exponentiating the difference of LS Means for the assay (Study 6, 5 through 11 years of age – Study 13, 12 years of age and older) and the corresponding CIs based on a linear regression model with baseline log-transformed neutralizing titers, postbaseline infection status, and vaccine group as covariates.
- SARS-CoV-2 NT50 were determined using a validated 384-well assay platform (Omicron subvariant XBB.1.5).
- Noninferiority is declared if the lower bound of the 2-sided 95% CI for the GMR is greater than 0.67 and the point estimate of the GMR is  $\geq 0.8$ .

**Table 28: Difference in Percentages of Participants With Seroresponse Between Study 6 and Study 13 Participants at 1 Month After the Study Vaccination – Evaluable Immunogenicity Population**

	Study 6 COVID-19 Vaccine-Naïve 5 Through 11 Years of Age COMIRNATY*		Study 13 COVID-19 Vaccine-Experienced ≥12 Years of Age COMIRNATY*		Difference	
SARS-CoV-2 Neutralization Assay	N <sup>a</sup>	n <sup>b</sup> (%) (95% CI <sup>c</sup> )	N <sup>a</sup>	n <sup>b</sup> (%) (95% CI <sup>c</sup> )	% <sup>d</sup>	95% CI <sup>e</sup>
Omicron XBB.1.5 - NT50 (titer) <sup>f</sup>	285	253 (88.8) (84.5, 92.2)	300	231 (77.0) (71.8, 81.6)	8.97	(3.91, 14.02) <sup>g</sup>

Abbreviations: CI = confidence interval; LLOQ = lower limit of quantitation; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: Seroresponse is defined as achieving a  $\geq 4$ -fold rise from baseline. If the baseline measurement is below the LLOQ, a postvaccination assay result  $\geq 4 \times \text{LLOQ}$  is considered a seroresponse.

- \* Vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Omicron XBB.1.5.
- N = Number of participants with valid and determinate assay results for the specified assay both before vaccination and at the given sampling time point. This value is the denominator for the percentage calculations.
  - n = Number of participants with seroresponse for the given assay at the given sampling time point.
  - Exact 2-sided 95% CI based on the Clopper and Pearson method.
  - Adjusted difference in proportions based on the Miettinen and Nurminen method stratified by baseline neutralizing titer category (< median, ≥ median), expressed as a percentage (Study 6, 5 through 11 years of age – Study 13, 12 years of age and older). The median of baseline neutralizing titers was calculated based on the pooled data in 2 comparator groups.
  - 2-sided 95% CI, based on the Miettinen and Nurminen method for the difference in proportions stratified by baseline neutralizing titer category (< median, ≥ median), expressed as a percentage.
  - SARS-CoV-2 NT50 were determined using a validated 384-well assay platform (Omicron subvariant XBB.1.5).
  - Noninferiority is declared if the lower bound of the 2-sided 95% CI for the adjusted difference in percentage of participants with seroresponse is greater than -10.0%.

## 15 REFERENCES

- Jain SS, Anderson SA, Steele JM, et al. Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV) multicenter study. *Lancet*. 2024;76:1-13.  
<https://doi.org/10.1016/j.eclinm.2024.102809>

## 16 HOW SUPPLIED/STORAGE AND HANDLING

COMIRNATY is supplied as follows:

- COMIRNATY Single-Dose Prefilled Syringes for Individuals 65 Years of Age and Older and Individuals 12 Years Through 64 Years of Age with at Least One Underlying Condition that Puts Them at High Risk for Severe Outcomes from COVID-19:
  - Carton of 10 single-dose prefilled syringes: NDC 0069-2528-10
  - Single-dose prefilled syringe: NDC 0069-2528-01
  - Supplied in prefilled syringes labeled with gray borders
- COMIRNATY Single-Dose Vials for Individuals 5 Through 11 Years of Age with at Least One Underlying Condition that Puts Them at High Risk for Severe Outcomes from COVID-19:
  - Carton of 10 single-dose vials: NDC 0069-2501-10
  - Single-dose vial: NDC 0069-2501-01
  - Supplied in vials with blue caps and labeled with blue borders

During storage, minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.

Do not use the vaccine after the expiration date printed on the vials, prefilled syringes, and cartons.

### Storage Prior to Use

#### *Prefilled Syringes*

Store COMIRNATY prefilled syringes refrigerated at 2°C to 8°C (35°F to 46°F). DO NOT FREEZE.

The total time out of refrigeration (at temperatures between 8°C and 25°C (46°F and 77°F)) must not exceed 12 hours.

### *Single-Dose Vials*

COMIRNATY single-dose vials may arrive frozen at ultra-cold conditions in thermal containers with dry ice. Once received, frozen vials may be immediately transferred to the refrigerator at 2°C to 8°C (35°F to 46°F), thawed and stored for up to 10 weeks. The 10-week refrigerated expiry date should be recorded on the carton at the time of transfer. Cartons of 10 single-dose vials may take up to 2 hours to thaw at this temperature. Once thawed, they should not be refrozen.

Alternatively, single-dose vials may be stored in an ultra-low temperature freezer at -90°C to -60°C (-130°F to -76°F). Do not store vials at -25°C to -15°C (-13°F to 5°F).

Cartons of COMIRNATY single-dose vials may be received at 2°C to 8°C (35°F to 46°F), and they should be stored at 2°C to 8°C (35°F to 46°F). Check that the carton has been previously updated to reflect the 10-week refrigerated expiry date.

The total time out of refrigeration (at temperatures between 8°C and 25°C (46°F and 77°F)) must not exceed 12 hours.

## **17 PATIENT COUNSELING INFORMATION**

Advise the vaccine recipient or caregiver to read the FDA-approved patient labeling.

Inform the vaccine recipient or caregiver of the potential benefits and risks of vaccination with COMIRNATY.

Advise the vaccine recipient or caregiver to report any adverse events to their healthcare provider or to the Vaccine Adverse Event Reporting System at 1-800-822-7967 and [www.vaers.hhs.gov](http://www.vaers.hhs.gov).

This product's labeling may have been updated. For the most recent prescribing information, please visit <https://dailymed.nlm.nih.gov/dailymed/>.

**BIONTECH**

Manufactured for  
BioNTech Manufacturing GmbH  
An der Goldgrube 12  
55131 Mainz, Germany



Manufactured by  
Pfizer Inc., New York, NY 10001

LAB-1490-16.0

US Govt. License No. 2229

**INFORMATION FOR RECIPIENTS AND CAREGIVERS**  
**COMIRNATY (Cuh-mir'-na-tee)**  
**(COVID-19 VACCINE, mRNA)**  
**(2025-2026 Formula)**

This summary is not intended to take the place of talking with your or your child's healthcare provider. If you have questions or would like more information, please talk with the healthcare provider.

**What is COMIRNATY?**

COMIRNATY is a vaccine to protect against COVID-19. COMIRNATY is for people who are:

- 65 years of age and older, or
- 5 years through 64 years of age at high risk for severe COVID-19.

Vaccination with COMIRNATY may not protect all people who receive the vaccine.

COMIRNATY does not contain SARS-CoV-2, the virus that causes COVID-19. COMIRNATY cannot give you or your child COVID-19.

**Who should not get COMIRNATY?**

You or your child should not get COMIRNATY if you or your child had:

- a severe allergic reaction after a previous dose of COMIRNATY or any Pfizer-BioNTech COVID-19 vaccine
- a severe allergic reaction to any ingredient in these vaccines (see **What are the ingredients in COMIRNATY?**).

**Before getting COMIRNATY, tell the vaccination provider about all of your or your child's medical conditions, including if you or your child:**

- have any allergies
- had a severe allergic reaction after receiving a previous dose of any COVID-19 vaccine
- have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)
- have a fever
- have a bleeding disorder or are on a blood thinner
- are immunocompromised or are on a medicine that affects the immune system
- are pregnant or plan to become pregnant
- are breastfeeding
- have received another COVID-19 vaccine
- have ever fainted in association with an injection

**How is COMIRNATY given?**

COMIRNATY is given as an injection into the muscle.

## **What are the risks of COMIRNATY?**

There is a remote chance that COMIRNATY could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose. For this reason, the vaccination provider may ask you or your child to stay at the place where you or your child received the vaccine for monitoring after vaccination. Signs of a severe allergic reaction can include:

- Difficulty breathing
- Swelling of the face and throat
- A fast heartbeat
- A bad rash all over the body
- Dizziness and weakness

Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines, including COMIRNATY and Pfizer-BioNTech COVID-19 vaccines. Myocarditis and pericarditis following administration of mRNA COVID-19 vaccines have occurred most commonly in males 12 years through 24 years of age. In most of these people, symptoms began within a week following vaccination. Based on available data, estimated rates of myocarditis and/or pericarditis from 1 through 7 days after getting a dose of the 2023-2024 Formula of mRNA COVID-19 vaccines were approximately 8 cases per million doses in people 6 months through 64 years of age and approximately 27 cases per million doses in males 12 years through 24 years of age.

In most people who have had myocarditis or pericarditis after receiving an mRNA COVID-19 vaccine, symptoms have gone away a few days after receiving treatment with medicines used to reduce inflammation.

In a study, follow-up information was collected on people who developed myocarditis after receiving the original formula of a COVID-19 vaccine; most people had received an mRNA COVID-19 vaccine. Some people in the study reported having heart symptoms approximately 3 months after developing myocarditis. Some people in the study had heart MRIs (scans that show detailed images of the heart muscle) initially after developing myocarditis and again approximately 5 months later. The initial and follow-up heart MRIs commonly showed signs of injury to the heart muscle, with improvement over time in most people. It is not known if these heart MRI findings might predict long-term heart effects of myocarditis. Studies are underway to find out if there are long-term heart effects in people who have had myocarditis after receiving an mRNA COVID-19 vaccine.

You should seek medical attention right away if you or your child have any of the following symptoms after receiving COMIRNATY, particularly during the 2 weeks after receiving a dose of the vaccine:

- Chest pain
- Shortness of breath
- Feelings of having a fast-beating, fluttering, or pounding heart

These could be symptoms of myocarditis or pericarditis.

Additional symptoms, particularly in children, may include:

- Fainting
- Unusual and persistent fatigue or lack of energy

- Persistent vomiting
- Persistent pain in the abdomen
- Unusual and persistent cool, pale skin

Side effects that have been reported with COMIRNATY or Pfizer-BioNTech COVID-19 vaccines include:

- Severe allergic reactions
- Non-severe allergic reactions such as rash, itching, hives, or swelling of the face
- Myocarditis (inflammation of the heart muscle)
- Pericarditis (inflammation of the lining outside the heart)
- Injection site reactions: pain, swelling, redness, arm pain
- General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph nodes (lymphadenopathy), decreased appetite, diarrhea, vomiting, dizziness
- Fainting in association with injection of the vaccine
- Febrile seizures (convulsions during a fever) in children 5 through 11 years of age

These may not be all the possible side effects of COMIRNATY. Ask your or your child's healthcare provider about any side effects that concern you.

Report vaccine side effects to FDA/CDC Vaccine Adverse Event Reporting System (VAERS). The VAERS toll-free number is 1-800-822-7967 or report online to <https://vaers.hhs.gov/reportevent.html>.

In addition, you can report side effects to Pfizer Inc. at 1-800-438-1985 or [www.pfizersafetyreporting.com](http://www.pfizersafetyreporting.com).

### **What if you or your child are pregnant or breastfeeding?**

If you or your child are pregnant or breastfeeding, discuss your options with the healthcare provider.

## What are the ingredients in COMIRNATY?

COMIRNATY contains the following ingredients:

- messenger ribonucleic acid (mRNA)
- lipids (((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 2-(polyethylene glycol 2000)-N,N-ditetradecylacetamide, 1,2-distearoyl-sn-glycero-3-phosphocholine, and cholesterol)
- tromethamine
- tromethamine hydrochloride
- sucrose

COMIRNATY does not contain preservatives.

This Information for Recipients and Caregivers may have been updated. For the most recent Information for Recipients and Caregivers, please visit <https://dailymed.nlm.nih.gov/dailymed/>.

If you have questions, talk to your healthcare provider or visit [www.COMIRNATY.com](http://www.COMIRNATY.com) or call 1-877-VAX-CO19 (1-877-829-2619).

**BIONTECH**

Manufactured for

BioNTech Manufacturing GmbH

An der Goldgrube 12

55131 Mainz, Germany



Manufactured by

Pfizer Inc., New York, NY 10001

LAB-1587-7.0

US Govt. License No. 2229

Revised: 8/2025